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Abstract
Cancer is a complex disease that is the result of different types of genetic
and epigenetic alterations. To gain a complete view of the tumorigenic
process it is crucial to bring together complementary data sources. In this
thesis, I describe IntOGen, an integrative framework that collects, ana-
lyzes and merges together different high-throughput functional genomic
data. It provides data from many different types of cancers and also en-
ables the interpretation of genome-wide data sets in the context of other
studies and other cancer types. Since it is updatable and extendable, it also
provides a framework upon which a system for the analysis of new types
of oncogenomics data can be built. In addition to IntOGen, I propose a
methodology based on sample-level enrichment analysis. This approach
can be used to detect clinically relevant patient subgroups in IntOGen
cancer data sets.
Resum
El càncer és una malaltia complexa resultant de diversos tipus d’alteracions
genétiques i epigenétiques. Per a aconseguir una visió completa del procés
tumoral és essencial unir diverses fonts de dades complementáries. En
aquesta tesi descric IntOGen, un marc d’integració que recull, analitza i
fusiona diverses dades de genòmica funcional extretes amb tècniques d’alt
rendiment. Aquest proporciona dades de diversos tipus de càncer i alhora
permet la interpretació de conjunts de dades a nivell de tot el genoma en
el context d’altres estudis i d’altres tipus de càncer. En ésser actualitza-
ble i extensible també proporciona un marc sobre el qual es pugui cons-
truir un sistema per a l’anàlisi de nous tipus de dades oncogenòmiques.
Addicionalment a IntOGen, proposo una metodologia basada en l’anàlisi
d’enriquiment a nivell de mostres individuals. Aquest enfocament pot
ésser emprat per a detectar subgrups de pacients amb rellevància clı́nica
als grups de dades de càncer a IntOGen.
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1.1 Preface
“Human biology is actually far more complicated than we imagine. Ev-
erybody talks about the genes that they received from their mother and
father, for this trait or the other. But in reality, those genes have very lit-
tle impact on life outcomes. Our biology is way too complicated for that
and deals with hundreds of thousands of independent factors. Genes are
absolutely not our fate. They can give us useful information about the
increased risk of a disease, but in most cases they will not determine the
actual cause of the disease, or the actual incidence of somebody getting
it. Most biology will come from the complex interaction of all the proteins
and cells working with environmental factors, not driven directly by the
genetic code.“
Craig Venter, pioneer genomic researcher after his genome was se-
quenced
Cancer is a complex disease of the genome. It begins with a sequence
of events that leads to a highly proliferative population of cells. More-
over, it is a disease that have profound socioeconomical effects. One in
every third of us will get cancer at some point in life and one fifth will
die because of cancer. Therefore, it is an inevitable part of our mod-
ern life style and will become more so because our life expectancy has
been increasing steadily during the last century. It has been deemed so
important that a national cancer act was enacted in the USA in 1971 to
strengthen the public effort to find a cure for cancer. Since then we have
improved our understanding of cancer biology and have developed more
effective cancer treatments, such as targeted drug therapies. However,
despite significant progress in the treatment of certain forms of cancer
such as childhood leukemia, cancer in general remains a major cause of
death. Therefore, our so-called ’war on cancer’ has not been won yet and
will never be won unless we employ biologically sound ways to combat
it. Decline in age-adjusted mortality rates in the last for decades is, in
most part, due to cancer screening and behavioral changes. Hence, one
could easily say that the best way to fight cancer can, most of all, be done
6
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through prevention. According to the World Health Organization, at least
one-third of all cancer cases are preventable given that the vast majority
of risk factors are environmental and life-style related. Prevention, which
refers to all kinds of activities (or avoidance of some) that help reduce
the incidence of cancer, is the most cost-effective strategy to control. For
example, tobacco causes many different types of cancer including cancer
of the lung, esophagus, larynx, mouth, throat, kidney, bladder, stomach
and cervix. In 2004, it caused en estimated 22% of cancer deaths world-
wide. Hence it is important to keep in mind how environmental factors
alter the incidence. Of course, prevention strategies are not enough on
their own. A thorough understanding of cancerogenesis can be obtained
only through the study of cancer and is very important for us to develop
treatment strategies that can turn cancer to a chronic disease. In this intro-
ductory chapter, I begin by introducing the most important conceptualiza-
tions of cancer formation and progression developed in the last century.
The model of cancerogenesis we assume effects substantially the way we
should study it and the biological aspects we ignore will be the reasons
why our attempts at tackling the problem will fail. The second part sum-
marizes the first high-throughput studies of cancer proving the case on the
use of genome-wide techniques to study cancer. Finally the last part gives
a taste of the latest technologies and their impact on the study of cancer. It
is becoming clear that generation of genome-wide data will lead the way
while methods for analysis and interpretation have so far lagged behind.
1.2 Models of Cancer Initiation and Progres-
sion
Cancerogenesis is a complex and mostly multi-step process that leads to
tumor formation. Cancer cells acquire genetic and/or epigenetic changes
resulting in the activation of oncogenes or inactivation of tumor suppres-
sor genes (TSG). These changes lead to a set of phenotypic characteristics
that confer a growth advantage to the cancer cell to survive in tumor mi-
croenvironment. Described by Hanahan and Weinberg, these ’hallmark’
7
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capabilities include ’sustaining proliferative signaling’, ’evading growth
suppressors’, ’enabling replicative immortality’, ’tumor promoting in-
flammation’, ’activating invasion and metastasis’, ’inducing angiogene-
sis’, ’genome instability and mutation’, ’resisting cell death’ and ’deregu-
lating cellular energetics’ (shown in Figure 1.1)[Hanahan and Weinberg,
2011]. In the following sections, I touch briefly two models of how we
think cancer takes place. Some are century old while some are compara-
tively new.
Figure 1.1: Hallmarks of cancer. Most if not all cancers acquire the same
set of characteristics during their progression through various strategies.
(modified from [Hanahan and Weinberg, 2011])
1.2.1 Clonal Evolution Model
This model posits that genetic and/or epigenetic changes that provide hall-
mark properties fuel ’Darwinian somatic evolution’ in cancerous cell pop-
8
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Figure 1.2: Genetic model of colorectal cancerogenesis. Mutations in
APC, beta-catenin or axin genes are required for tumor initiation. Subse-
quent progression towards malignancy is accompanied by genomic insta-
bility and sequential mutations in K-ras, Smad4, p53 genes, as well as in
other unknown genes. (from [Pinto and Clevers, 2005])
ulations [Nowell, 1976]. These changes constitute the source of variation
leading to ’natural selection’ that results in the propagation of advanta-
geous traits and a more tumorigenic phenotype. This process has been
well-described for colorectal cancer [Fearon and Vogelstein, 1990]. Ac-
cording to this model, malignant colorectal carcinomas arise from pre-
existing benign adenomas through a multi-step process (Figure 1.2). In
tumor cell populations, different genetic/epigenetic properties are found
in different cells referred to as clones. These sub-populations can be dis-
cerned from each other according to their degree of differentiation, pro-
liferation, vascularity, inflammation, and/or invasiveness. Proliferation of
cells with advantageous traits leads to the generation of different clones in
the tissue. According to this model, most cells in the tumor can proliferate
to form new tumors. However, evidence from recent research has shown
that this might not be the case. There might be a new dimension of intra-
tumoral heterogeneity and a subclass of cells with exclusive neoplastic
properties. These ideas lead to a relatively new model of tumorigenesis
described in the next section.
This traditional view of how evolutionary processes lead to cancer centers
9
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around the idea that the initial and subsequent successive mutations in the
cancer cell population, which are random and cell-autonomous, activate
hallmark capabilities [Lambert et al., 2011]. A variation of this model is
the microenvironmental model which expands on this idea and proposes
a dynamic Darwinian model as a result of the interactions between two
somatic evolutionary processes: the emergence of adaptations in potential
cancer-forming cells to overcome the tumor suppression mechanisms of
the host organism; and the tumor suppressive strategies the organism de-
velops to reduce the probability of death from cancer prior to and during
reproductive maturity [Gatenby and Gillies, 2008, Gatenby and Brown,
2011]. The interplay between cells seeking survival under microenvi-
ronmental stress activates a survival programme that facilitates evolution
and adaptation of malignant and pre-malignant cells. This model pro-
poses that hallmarks of cancer, which are acquired during the formation
and progression of cancer, are actually microenvironmental stress barri-
ers. An invasive cancer emerges only after all these barriers are overcome.
Somatic evolution is, thus, the sequence of cellular adaptations to these
changing barriers. Another model in this line is proposed by Lambert
G. et al [Lambert et al., 2011]. They describe the environmental effect
as a programmed, deterministic and collective stress response that is per-
formed by cancer cells that have complex communication with the sur-
rounding microenvironment. They further propose that the evolutionary
strategies used by bacteria, such as the generation of genetic and phe-
notypic heterogeneity under external stress, parallel those used by tumor
cells [Lambert et al., 2011].
1.2.2 Cancer Stem Cell Model
The stem cell concept is several decades old. Although it was already
known that tumors have histological heterogeneity, it was first established
in 1937 that a single cell from a mouse tumor could be used to initiate a
new tumor in recipient mouse [Furth, 1937]. Based on research on soft tis-
sue cancers, the early definition of CSC model was proposed [Pierce and
Speers, 1988]. Early during 90’s, with the advent of fluorescence assisted
10
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cell sorting and xenograft assays, CSC model was revived. CD34+ and
CD38− cells were identified as CDC markers for acute myeloid leukemia
(AML) [Uckun et al., 1995]. However, the definitive turning point in this
model was the identification of CSCs (CD44+ and CD24−) in a solid
tumor (breast cancer) for the first time [Al-Hajj et al., 2003]. This and
subsequent work supported the model and led to some hot debate over
the existence and importance of the hierarchical structure in tumor tissues
proposed by the CSC model.
According to this model, ‘there is a small subset of cancer cells, the
cancer stem cells (CSCs), which constitute a reservoir of self-sustaining
cells with the exclusive ability to self-renew and maintain the tumor‘ [Fig-
ure 1.3] [Reya et al., 2001]. CSCs share important properties with normal
stem cells including self-renewal and differentiation capacity. This model
implies that cancers are hierarchically arranged with CSCs lying at the
apex of the hierarchy. First evidence for CSCs came from leukemia, in
which 0.01-0.1% of the tumor cell population can induce leukemia when
transplanted to immunodeficient mice. Later they were found in solid ep-
ithelial tumors. These cell subpopulations can be isolated using specific
cell surface markers and be used to seed new tumors in vivo. However,
there is much controversy surrounding this model, most arising from the
definition of CSCs. Currently it is unknown whether CSCs can give rise to
multiple differentiated cell types in the tumor similar to the way stem cells
in normal tissues do. Recent studies show that the proportion of CSCs in
cancer cell population may be a function of the cell type of origin, stro-
mal microenvironment, accumulated somatic mutations, stage of malig-
nant progression reached by a tumor and the animal model used to mea-
sure CSC representation[Gupta et al., 2009]. Another unclear point about
CSCs is the origin of their precursors. In some tissues, normal tissue stem
cells may undergo oncogenic transformation giving rise to CSCs; while
in others partially differentiated transit-amplifying cells, progenitor cells,
may undergo oncogenic transformation becoming more stem-like [Hana-
han and Weinberg, 2011]. In this respect, epithelial-to-mesenchymal tran-
sition (EMT), a mechanism of interconversion of cells from one state of
differentiation to another during embryogenesis, has been studied in the
11
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acquisition of CSC-like properties. Carcinoma cells at the invasive edges
of tumors have been observed to undergo EMT under the influence of
contextual signals they receive from surrounding stroma tissue. However,
the idea of EMT also brings into question the prevalence of bidirectional
convertibility of cell sub-poplutations in cancer tissue. Indeed, if such
plasticity is to be found in tumors, a dynamic equilibrium should exist
between CSCs and non-CSCs, which can be shifted in one direction or
another by the contextual signals within the tumor microenvironment. Al-
though the notion of interconvertibility does not undermine the concept of
CSCs, if the rate of conversion is high, this trivializes the importance of
CSCs. However, the existing literature indicates that this is not the case,
CSCs exit in a metastable state, they can perpetuate themselves indefi-
nitely, and the flux of non-CSCs into CSCs is relatively low and, in some
cases, possibly nonexistent [Gupta et al., 2009].
Finally, the CSC model also has implications for cancer treatment.
CSCs and cancer cells arising from EMT are more resistant to conven-
tional therapeutics than their non-CSC or nonmesenchymal counterparts
[Gupta et al., 2009]. This may explain almost-inevitable recurrence even
after successful debulking of tumors by conventional cancer therapies.
Moreover, since current therapeutic strategies target non-CSC are not ef-
fective against CSCs, there is a need for developing CSC-specific thera-
pies. However, if interconversion is indeed prevalent in cancer popula-
tions, the latter would not be enough to eradicate the whole cancer cell
population. Hence, the answer to this challenge could be combination
therapies that attack both cell populations at the same time.
1.3 Oncogenomics
1.3.1 Introduction
The study of the genetic basis of cancer has undergone a profound
transformation in the last decade. Until recently, most cancer genes had
been identified by using traditional methods such as positional cloning
and therefore scientists had to focus on particular candidate genes. To-
12
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Figure 1.3: Two models of tumor heterogeneity. Recent studies show
that there is extensive phenotypical and functional heterogeneity in tu-
mor cell populations. There are two theories as to how this heterogeneity
arises. According to the clonal evolution model, tumor cells are biologi-
cally equivalent, but their behavior is influenced by intrinsic and extrinsic
factors and is therefore both variable and unpredictable. Thus, tumor-
initiating activity cannot be enriched by sorting cells based on intrinsic
characteristics. In contrast, the cancer stem cell model postulates the ex-
istence of biologically distinct classes of cells with differing functional
abilities and behaviors. Only a subset of cells can initiate tumor growth;
these cells possess self-renewal ability and give rise to nontumorigenic
progeny that make up the bulk of the tumor. This model predicts that
tumor-initiating cells can be identified and purified from the bulk nontu-
morigenic population based on intrinsic characteristics. (modified from
[Dick, 2008])
13
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day, high-throughput techniques allow scientists to analyze alterations
in a large number of genes at the same time, with a single assay. Con-
sequently several ’omics’ fields have spawned (Figure 1.4). For exam-
ple, large-scale genomic alterations such as chromosomal rearrangements
and imbalances can be studied with cytogenetic methods such as com-
parative genome hybridisation (CGH). Another prevalent technique is
cDNA/oligonucleotide microarrays, which can be used to assess the tran-
scriptomic level of thousands of genes. Studies have shown that tran-
scriptomic profiles of tumors are not only clinically relevant in multiple
cancer types, they can also be used to define cancer subtypes or to predict
response to therapy regimen. The use of mutational profiling to detect
mutations in the kinome (all kinase genes) as well as the exome (all ex-
ons) in tumor genomes has yielded important results over the past few
years. And recently there are epigenomic high-throughput methods to
study the DNA or histone methylome and all the other histone modifi-
cations. The possible ways in which the activity of genes can be altered
prompted the design of studies which include the high-throughput anal-
ysis of different alterations in the same tumor samples. Now it is clear
that the amount of work that should be done to gain a glimpse of the
changes in cancer is much more than a single research group can under-
take. This realization led to several big, collaborative projects that aim
to identify all genetic alterations in common tumor types using genome-
wide, high-throughput techniques. Examples are The Cancer Genome At-
las (http://cancergenome.nih.gov) of the NIH, the Cancer Genome Project
(http://www.sanger.ac.uk/genetics/CGP) at the Sanger Institute, and the
International Cancer Genome Consortium (http://www.icgc.org/).
The application of these ’omics’ technologies to the study of can-
cer provides an unprecedented opportunity to understand the mechanism
of cancerogenesis. The enormous amount of data obtained using these
methodologies can be used to identify possible targets for therapy, dis-
cover molecular biomarkers that allow early detection, improve diagno-
sis/prognosis and last but not least predict response to therapies. However,
with big data come big difficulties. The application of these technologies
yields large volumes of data. One of the many challenges is sorting out
14
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Figure 1.4: Oncogenomics. Landscape of oncogenomics analyses. Com-
plete understanding of oncogenesis requires the study of all possible al-
terations that take place in cancer cells. The integrated analysis of DNA,
RNA and methylation sequencing data will help elucidate all relevant ge-
netic changes in cancers. Another important component of genome-wide
interrogation is pathway analysis usually using gene set enrichment meth-
ods. (from [Ding et al., 2010b])
15
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the alterations that are causative (driver alterations), from those that are
not directly involved in tumor development but are only byproducts of
the proliferative life style of cancer cells (passenger alterations). Hence
it is necessary to develop new methods to be able to prioritize the more
promising candidates from genes that are unlikely to be contributing to
tumorigenesis.
The analysis at the level of individual genes is crucial and informa-
tive but does not capture the full complexity of biological systems. Thus,
it is also important to study the alterations identified in cancer cells at a
more general level. One way to approach this is by focusing on the im-
portance of functional or regulatory functions performed by genes rather
than on the involvement of genes themselves (Figure 1.4). Some of these
approaches have been used in the analysis of microarray data, for exam-
ple the ’module maps’ and ’molecular concept maps’.
The most recent trend in cancer research is the exploitation of data
from different types of alterations obtained with different techniques. A
number of studies have revealed the effectiveness of these integrative ap-
proaches, whereby information from complementary experimental data
sources are combined to provide greater insight to the process of tumori-
genesis. Next I will review the main types of genomic alterations involved
in cancer and the techniques used for their study along with related sem-
inal studies. At the end of the chapter I discuss different approaches for
the integration and analysis of this complex data.
1.3.2 Somatic Mutations
The somatic mutations encompass several distinct types of changes in ge-
nomic DNA sequence that take place in somatic cells of the individual
but not in the germ line [Stratton et al., 2009]. In addition to point muta-
tions, they encompass lesions affecting bigger regions (Figure 1.5). These
include:
1. point mutations (substitutions of one base by another);
2. insertions/deletions of small/large segments of DNA;
16
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3. rearrangements (a piece of DNA is broken and joined to another
segment of DNA);
4. gene amplification (copy number increases more than two copies
present in the diploid genome)
5. gene loss (copy number reductions leading to complete loss of the
DNA sequence of a gene)
6. acquired exogenous DNA sequences (for example from viruses such
as human papilloma virus, Epstein Barr virus)
7. somatic mutations in the mitochondrial genome
Over the lifetime of an individual, all these different types of muta-
tions accumulate in the genome when DNA is continuously damaged by
internal and external mutagenic factors. Most of these damages are re-
paired. However, the repair mechanisms are error-prone, so a small frac-
tion of the damage cannot be fixed (or fixed incorrectly) leading to the
propagation of these mutations. So there would already be an intrinsic
source of mutation even if there were no other mutagenic factors present.
We do not know the exact mutations rates, but we do know that it differs
from cell type to cell type and are affected by inherited diseases. The
extent of physical exposure to exogenous mutagens (e.g. tobacco smoke,
aflatoxins) is also an important external factor. The rest of the mutations
emerge beginning from the first signs of neoplastic transformation in the
cell. For some cancers, this period is characterized by a ’mutator pheno-
type’, which increases the mutation rate, such as the effect of mismatch
repair deficiencies in colorectal cancer [Loeb et al., 1974, Loeb, 2001].
High mutation rates provide an advantage to the cancer cell since it in-
creases variability in the tumor cell population. However, it has also been
argued that mutator phenotype is not a requirement of tumorigenesis. Fi-
nally, a certain fraction of mutations will take place because of the dis-
turbance of tumor populations with therapies such as chemotherapy and
targeted therapy. These mutations are usually found in recurrences.
It is assumed that all the somatic mutations in a tumor happen over
17
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Figure 1.5: Chromosomal Abnormalities. There are two main classes of
chromosomal abnormalities in cancer. Balanced chromosomal rearrange-
ments are those changes that lead to the formation of a chimeric fusion
gene and those that lead to the aberrant juxtaposition of gene regulatory
elements to the coding sequence of a structurally intact gene. The forma-
tion of a chimeric fusion gene results in the expression of a chimeric pro-
tein with new or altered activity. In the majority of cases, only one of the
two fusion genes generated and not the reciprocal counterpart (indicated
by the dashed arrows) contributes to cancer pathogenesis. The deregu-
lated expression of a structurally normal gene results in deregulated ex-
pression of a normal protein. Chromosomal imbalances can be either ge-
nomic gains and genomic losses. Genomic gains include complete or par-
tial trisomies and intrachromosomal or extrachromosomal amplifications,
which can be identified cytogenetically as homogeneously staining re-
gions (HSR) and double-minute chromosomes (dmin), respectively. HSR
are chromosomal regions that display no typical banding pattern; dmin
are circular, acentric, autonomously replicating DNA strands of varying
size; mRNA denotes messenger RNA. Genomic losses include mono-
somies and large-scale or submicroscopical deletions. (from [Frohling
and Dohner, 2008])
18
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a long period of time. However, recent studies have shown that the ac-
cumulation of mutations does not have to be extended over a time period
progressively, but instead mutations might emerge abruptly. An example
to this is ’chromothripsis’. This is a new mechanism of cancer develop-
ment proposed to affect 2-3% of cancers but usually bone cancers. With
a single event a chromosome can be fragmented to hundreds of pieces.
This is followed by the erroneous joining together of the pieces [Stephens
et al., 2011].
All these mutations, whatever the mechanism of generation or struc-
tural nature, have certain consequences for cancer development. Accord-
ing to this criteria they can be classified as ’drivers’ and ’passengers’.
Driver mutations confer a selective advantage to the cancer cell. They
directly contribute to tumorigenic phenotype. The rest of the mutations,
which constitute a large part, are assumed to be passengers, just byprod-
ucts of the oncogenic process. Sorting out the drivers from passengers is
a daunting task requiring analysis of high-throughput data using sophis-
ticated computational methods. The number of driver mutations neces-
sary and sufficient for cancer formation depends on the cancer type, with
breast, colorectal and prostate cancers probably having five to seven muta-
tions while hematopoietic malignancies require fewer mutations [Miller,
1980]. Although recent studies report a greater number of mutations,
this subject is still not well established [Beerenwinkel et al., 2007]. Cur-
rently these mutations have been shown to recurrently affect a census
of 350 genes. These constitute the Cancer Gene Census [Futreal et al.,
2004]. The majority of these genes were found using classical experimen-
tal methods such as low-resolution cytogenetical assays or through the
linkage analysis of families affected by familial forms of cancers. Some
of these mutations are common across different cancer types (TP63, RB1)
while others are specific to a certain cancer type. Another characteristic of
these cancer genes is that they cluster on certain signalling pathways. One
common example is MAPK/ERK pathway. Upstream components like
cell-surface receptors as well as downstream cytoplasmic components of
this pathway have been found to be mutated. This idea forms the rationale
behind modular enrichment analysis mentioned earlier.
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Chromosomal rearrangements
Genomic rearrangements are very important determinants of human health
and disease. While they play fundamental roles in the generation of a vast
diversity of antigen receptors essential to fight pathogens, they are also
implicated with various human disorders including cancer. They cause
structural variation in the genome and bring together distant parts of the
genome [Frohling and Dohner, 2008] (Figure 1.5). They range in size
from a few hundred base pairs to several megabases including reciprocal
translocations, inversions, and insertions or combinations of these. Evi-
dence has shown that these alterations might take place early during tu-
morigenesis or might also be initiating events. Moreover, these alterations
can also be used to differentiate different subtypes of a cancer with dis-
tinct histopathological properties or as indicators of response to a certain
type of therapy. Until recently chromosomal rearrangements were exclu-
sively identified in hematopoietic malignancies or tumors of mesenchy-
mal origin. However, recent studies showed that they also play important
roles in common epithelial tumors such as prostate cancer and small-cell
lung cancer. Functionally, these alterations can result in the generation
of chimeric fusion genes with new or altered function or chromosomal
changes that lead to the alteration of the expression of a normal gene.
Chimeric fusion genes are formed by the fusion of parts of two different
genes. These genomic rearrangements were thought to be random. How-
ever, it became evident that they are influenced by cell-type, cell stage and
genomic context; can be triggered by environmental or cellular cues; and
need not be causal in cancer [Mani and Chinnaiyan, 2010] (Figure 1.6).
The genes inflicted by this type of alteration are usually tyrosine kinases
and transcription factors [Frohling and Dohner, 2008].
The prototypical example for gene fusions involving kinase genes is
the Philadelphia chromosome, which is the result of a reciprocal translo-
cation, in which sequences of the BCR gene on band 22q13.23 are joined
to portions of the gene encoding ABL1 tyrosine kinase on band 9q34.1
[Nowell, 2007]. The resulting chimeric protein, BCR-ABL1, contains
the catalytic domain of ABL1 and a domain of BCR that mediates con-
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Figure 1.6: Triggers for genomic rearrangements. There is a series
of criteria to be fulfilled for genomic rearrangements to occur. 1) The
sequences involved should be in close proximity in order to be joined to-
gether. This proximity can be cell-type specific or induced by particular
signaling pathways. 2) There has to be a DNA break or template strand
switch during replication. The former can be induced by various factors
such as cellular stress, the mode of DNA repair and DNA sequence. Some
sequences are more prone to rearrangements owing to their structure, epi-
genetic modifications and ability to recruit endonucleases. (from [Mani
and Chinnaiyan, 2010])
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stitutive oligomerization of the fusion protein leading to aberrant tyro-
sine kinase activity. BCR-ABL1 fusion is present in all patients with
chronic myeloid leukemia and 20% of patients with acute lymphoblastic
leukemia, and in rare cases of acute myeloid leukeamia. The importance
of this fusion gene led to the use of a selective tyrosine kinase inhibitor as
a treatment in clinic, imatinib mesylate [Goldman and Melo, 2003]. Fur-
thermore, the detection of imatinib-resistant kinase mutations in patients
that develop resistance to imatinib led to the design of second-generation
of BCR-ABL1 inhibitors such as dasatinib and nilotinib [Kantarjian et al.,
2006, Shah et al., 2004, Talpaz et al., 2006]. Tyrosine kinase fusion genes
and related aberrant tyrosine signaling have been shown to be in epithelial
tumors also such as prostate and lung cancers [Tomlins et al., 2005a, Soda
et al., 2007]. Genomic rearrangements were thought to be random. How-
ever, it became evident that they are influenced by cell-type, cell stage and
genomic context; can be triggered by environmental or cellular cues; and
need not be causal in cancer [Mani and Chinnaiyan, 2010] (Figure 1.6).
Chromosomal rearrangements involving transcription factors (TFs)
might lead to enhanced, aberrant or repressed transcriptional activity. Al-
most all cases of Ewing sarcoma have a gene fusion that join EWSR1
gene to one of the ETS transcription factors. The resulting fusion gene
contains the DNA binding domain of the ETS TF and a potent transacti-
vation domain of EWSR1 gene leading to aberrant ETS transcriptional ac-
tivity [Delattre et al., 1992]. Although tumor suppressor fusion genes are
as prevalent as tyrosine kinase fusion genes, they have not been shown to
be attractive pharmacological targets yet. TF fusion genes can also result
in transcriptional inhibition. Fusion genes such as PML-RARA, RUNX1-
RUNX1T1 and CFBH-MYH11, contain the functional DNA binding do-
main of the TF and a protein that interacts with inhibitors of transcription.
Binding of these chimeric proteins lead to repression of the target genes
required for normal myeloid differentiation in the case for acute myeloid
leukemia. PML-RARA inhibition using all-trans retinoic acid and arsenic
trioxide has been shown to be remarkably effective in acute promyelocytic
leukemia.
Chromosomal rearrangements that juxtapose tissue-specific promo-
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tors or enhancer sequences to oncogenes results in the deregulation of ex-
pression of the oncogene. A good example is fusion genes that join the en-
hancer region of an immunohemoglobin gene with MYC TF, which cause
the aberrant up-regulation of the famous oncogene in Burkitt’s lymphoma.
Previously, chromosomal changes of this type were shown to be exclusive
to lymphoid cancers. But recently in prostate cancer, it was shown that
fusions involving ETS genes are distinguishing features of prostate can-
cer [Tomlins et al., 2005a]. These fusions, which include the ETS genes
ERG, ETV1, ETV4 and ETV5, are observed in most prostate cancers.
TMPRSS2-ERG is the most common one (36-78% of cases). These gene
fusions might be closely related to androgen receptor (AR) signaling. It
was proposed that androgen could induce chromosomal movements and
bring together the gene fusion partners, thereby facilitating the formation
of genomic rearrangements. Indeed, stimulation of androgen-sensitive
human prostate cancer LNCaP cells with the androgen receptor ligand di-
hydrotestosterone (DHT) induces intrachromosomal proximity between
TMPRSS2 and ERG and also interchromosomal proximity between TM-
PRSS2 and ETV1.
Techniques
The earliest methods to detect chromosomal rearrangements were cytoge-
netic techniques such as spectral karyotyping and fluorescence in situ hy-
bridization (FISH). These methods are based on the visualization of chro-
mosomes and chromosome banding patterns by microscopy. However
they lack the sensitivity to detect anything less than gross genomic rear-
rangements and provide limited resolution of breakpoint positions. More
recent array-based methods provide better resolution but cannot report on
balanced rearrangements or the fusion events that have occurred follow-
ing chromosome breakage. Both end-sequencing of BAC libraries de-
rived from cancer genomes [Volik et al., 2003] and hybridization of flow-
sorted chromosomes to arrays [Howarth et al., 2008] are labor-intensive
and therefore not applicable to large numbers of cancer genomes. Re-
cently, MacDonald and colleagues proposed a method called cancer out-
lier profiles analysis [MacDonald and Ghosh, 2006] to detect chromoso-
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mal rearrangements from expression data. This method was used in the
detection of TMPRSS2-ETS fusions in prostate cancer [Tomlins et al.,
2005a].
Chromosomal Imbalances
Chromosomal imbalances can be defined as gains or losses of genetic
material. They can involve regions as large as entire chromosomes to in-
tragenic duplications or deletions. Rarely the event includes a single gene
only, then determining the consequence is straight-forward. However,
when big regions with multiple genes are affected, it is difficult which
one(s) of the genes are the dominant reasons of the event. Hence, unlike
chromosomal rearrangements, the consequences of most chromosomal
imbalances are unknown. Nonetheless, integration of information from
different types of genome-wide analysis such as copy number, expression
and functional genomic techniques can help pinpoint the gene-of-interest
within the genomic regions affected by the event.
Genomic gain or amplification leads to the over-expression of the
genes in the target region. A very famous example is ERBB2 gene, which
is amplified in 30% of breast cancers [Hudis, 2007]. It is also the target
of a monoclonal antibody called trastuzumab. This type of chromosomal
imbalances can also cover very large regions. Integrative approaches have
been employed to filter the passenger genes in the regions affected. With
this strategy, new oncogenes have been found (MITF [Garraway et al.,
2005] and NEDD9 [Kim et al., 2006] in malignant melanoma and YAP1
and BIRC2 in hepatocellular carcinoma). Focal genomic gains, on the
other hand, are less common. High-resolution techniques helped greatly
in the detection of these events inflicting very small regions. For example,
it enabled the discovery of a small gain in ESR1 in some breast cancers
[Holst et al., 2007]. A recent study demonstrated the power of these meth-
ods. An amplification of 480-kb sequence was shown to affect two genes
in 12% of non-small-cell lung carcinoma [Stevenson et al., 2009]. Finally,
focal genomics gains of MET gene have also been shown in the develop-
ment of resistance to EGFR inhibitors in non-small cell lung carcinomas
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[Engelman et al., 2007].
The spectrum of genomic losses ranges from cytogenetically visible
monosomies to single-gene or intragenic deletions. This type of event
mostly results in the loss of function of the target gene(s). Since restora-
tion of gene function is more difficult than inhibition, it is not clear how
the information of genomic loss will provide therapeutic targets. Nev-
ertheless, dissection of the mechanisms through which genomics losses
promotes tumorigenesis can help find indirect targets. A good example is
the frequent loss of PTEN in glioblastoma, prostate cancer and endome-
trial cancer [Sansal and Sellers, 2004]. This loss leads to increasing sig-
naling through PI3K/AKT/mTOR pathway, which promotes proliferation
and survival. Evidence shows that PTEN-deficient tumors are sensitive to
mTOR inhibitors [Cloughesy et al., 2008, Neshat et al., 2001]. The study
of large scale genomic losses led to the discovery of important TSGs such
RB1, APC, PTEN, and ATM. However, in many cases the critical genes in
lost regions are not known. Nevertheless, even if we do not know the cul-
prits, the information of genomic loss can be used for determining prog-
nosis and guiding treatments (loss of 5q in acute myeloid leikemia). High-
throughput techniques have also made their impact in genomic losses.
Combination of HT-RNAi and HT-CNA led to the discovery of REST
gene as a TSG [Westbrook et al., 2005]. SNP arrays have been used to
detect the loss of PAX5 and IKZF1 in 30% of B-progenitor acute lym-
phoblastic leukemia and 80% of BCR-ABL1-positive acute lymphoblas-
tic leukemia [Mullighan et al., 2007, Mullighan et al., 2008]. Genomic
loss can also lead to allelic insufficiency. An example is monoallelic in-
activation of FAM123B gene in 21.6% of Wilms’ tumors [Rivera et al.,
2007]. Finally genomic losses can affect non-coding regions also. Loss
of tumor-suppressor microRNAs MIRN15A and MIRN16-1, both genes
inhibit anti-apoptotic gene BCL2, are deleted in 50% of chronic lympho-
cytic leukemia [Calin et al., 2002a].
Techniques
Comparative genomic hybridization was the first method to scan the en-
tire genome for DNA copy number changes [Kallioniemi et al., 1994].
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The procedure begins with the extraction of genomic DNA from both
the test and the reference cell populations, followed by differential label-
ing and hybridization to metaphase chromosomes. Relative hybridiza-
tion intensity of the test compared to the reference is proportional to
copy number difference. A variation of this method involves hybridiza-
tion to DNA microarrays which can contain large-insert genomic clones
such as BACs [Pinkel et al., 1998], PCR products [Dhami et al., 2005]
and oligonucleotides [Brennan et al., 2004]. Recently single nucleotide
polymorphism arrays (SNParray) have been used to determine copy num-
ber changes at a high resolution as well as for the detection of loss-of-
heterozygosity (LOH) [Lindblad-Toh et al., 2000]. More recently, tech-
niques based on NGS are also used. This is covered later on.
Nucleotide Substitutions, Small Insertion and Deletion Mutations
Nucleotide substitutions are the most common type of somatic genome
alteration in cancer. They occur at rate of 1/1,000,000 nucleotides. Small
insertion and deletion mutations, on the other hand, are ten fold less com-
mon than nucleotide substitutions. However, the rate of mutation varies
greatly from cancer sample to cancer sample. For example, ultra-violet-
induced melanomas and hypermutated tumors with defects in DNA re-
pair machinery can have rates as high as 10/1,000,000 nucleotides while
hematapoietic malignancies can have less than 1/1,000,000. Therefore, it
is important that the statistical analysis used to detect mutations take into
account this sample-to-sample variation in mutation rate.
Mutations can be classified in a variety of ways:
1. silent (no effect on the amino acid code), missense (change of the
original amino acid codon to another) or nonsense (change of the
original amino acid codon to a stop codon).
2. loss-of-function (the function is lost or weakened), gain-of-function
(the protein becomes more active or gains a new or abnormal func-
tion).
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3. transition (mutations changing a purine nucleotide to another purine
{A to G} or a pyrimidine to another pyrimidine {C to T}) and
transversion (change from a purine to a pyrimidine or vice versa).
Different types of mutations affect genes altered in cancers. However,
one can draw some generalizations in the mutational patterns observed.
For example, oncogenes usually undergo gain-of-function mutations. A
typical example is BRAF. One of the most common changes observed
in this kinase is the conversion of a valine to a glutamate at codon 599
within the activation loop of the kinase domain. This substitution leads to
the constitutive activation of the protein product even in the absence of an
activating signal. The mutated BRAF kinase phosphorylates downstream
targets leading to abnormal growth. On the other hand, tumor suppressor
genes are usually rendered non-functional by loss-of-function mutations.
A point mutation in TP53 inactivates its capacity to bind to the sequences
that it regulates transcriptionally. Mutated TP53 cannot do its normal
function of inhibiting cell growth and stimulating cell death in times of
stress.
Accumulation of somatic mutation data has been accelerated with the
advances in sequencing technologies which made it possible to determine
the mutational status of every gene in a cancer genome. However, a new
challenge is faced when differentiating the driver mutations among the
high number of passengers identified in such large-scale sequencing ef-
forts. Many factors should be taken into considerations related to the
mechanisms and selective pressure dominant in mutation process while
designing statistical methods to help the identification of driver mutations.
Such large-scale sequencing efforts initially focused on signalling path-
ways previously known to be mutated in at least one gene. In addition to
well known pathways, specific gene families have been scrutinised: ty-
rosine kinases, lipid kinases, tyrosine phosphatases and tyrosine kinase
receptors. These and similar studies pointed to the importance of kinase
and phosphatase mutations and led to the identification of some impor-
tant genes such as PI3KCA [Samuels et al., 2004], BRAF [Davies et al.,
2002], HER2 [Stephens et al., 2004], EGFR [Paez et al., 2004], JAK2
[Levine et al., 2005], UTX [van Haaften et al., 2009] and IDH1 [Parsons
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et al., 2008] in many tumors. While some of these genes were previously
known, some were unexpected. The discovery of mutations in a Krebbs
cycle gene, isocytrate dehydrigenase 1 (IDH1) in glioma is a good ex-
ample. This demonstrates the power of systematic and comprehensive
screens.
Important insights have been obtained from these early studies. First,
most point mutations are passengers while few are mutated at high fre-
quencies (”mountains” in the mutational landscape) [Wood et al., 2007,
McLendon et al., 2008, Parsons et al., 2008]. This applies to mutations
in intragenic and intergenic regions and exons. Most of these drivers are
mutated infrequently, probably conferring less selective advantage on a
cancer cell. This result also implies that the number of driver mutations
required for tumorigenesis may be much higher than the previously pre-
dicted number 5-7, but may be as many as 20 mutations [Greenman et al.,
2007]. Second, as stated earlier, mutation rate varies greatly from cancer
genome to cancer genome. Finally, there seems to be preference of mu-
tations for specific sequences. For example, in breast cancer, C-to-G sub-
stitutions occur on cytosine residues almost always following a thymine.
Techniques
The main method to detect single nucleotide mutations is sequencing.
The oldest sequencing method is chain terminator sequencing (Sanger
sequencing) [Sanger et al., 1977a, Sanger et al., 1977b]. The key prin-
ciple of the Sanger method was the use of dideoxynucleotide triphos-
phates (ddNTPs) with a label as DNA chain terminators during the syn-
thesis of DNA from a template. An improvement over this method was
the use of dye-terminators, which enables sequencing in a single reac-
tion. Recently high demand for low-cost and faster sequencing methods
has driven the development of new technologies. In 2005, the first two
of second-generation (then called next-generation) sequencing methods
arrived: the sequencing-by-synthesis technology developed by 454 Life
Sciences [Margulies et al., 2005] and the multiplex polony sequencing
protocol of George Church’s lab [Shendure et al., 2005]. Both methods
greatly reduce the reaction volume and parallelize the process by extend-
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ing the number of sequencing reactions. Competition between producers
led to longer and greater number of sequencing reads resulting in third
generation systems based on single-molecule analysis [Derrington et al.,
2010, Krivanek et al., 2010, Eid et al., 2009]. These technologies inter-
rogate single molecules of DNA overcoming issues related to the biases
introduced by PCR amplification and dephasing (a major limitation of
second-generation sequencing). More importantly, this new technology
offers longer reads (tens of bases to tens of thousands of bases per read),
higher throughput (the amount of DNA that can be processed per unit
time), faster turnaround time, higher consensus accuracy to enable rare
variant detection, small amounts of starting material and, of course, lower
cost.
1.3.3 Epigenomic Alterations
Epigenetic changes are defined as heritable changes in gene expression
that are not accompanied by changes in DNA sequence. Epigenetic pro-
cesses play important roles in gene silencing at chromatin level and hence
are implicated in orchestrating biological processes such as differentia-
tion, imprinting, X chromosome inactivation etc. Epigenetic alterations
are increasingly being recognized as central mechanisms of tumor de-
velopment. Because typical epigenomic features such as global DNA hy-
pomethylation and promoter-specific hypermethylation can be commonly
observed in benign neoplasias and early-stage tumors, it is becoming ap-
parent that epigenetic deregulation may precede the classical preliminary
transforming events: mutations in tumor suppressors, proto-oncogenes, or
both, and genomic instability. The following are the types of epigenetic
alterations that take place in cancer [Jones and Baylin, 2007]:
1. DNA methylation takes place across all the genome and its disrup-
tion is a hallmark of cancer. In normal cells, CpG islands and CpG
island shores are usually unmethylated while there is methylation
in the gene body (Figure 1.7). These two properties allow gene
transcription and avoid spurious transcriptional initiation, respec-
tively. On the other hand, in cancer cells, CpG islands and CpG
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Figure 1.7: DNA methylation patterns in normal and cancer cells. (a)
In normal cells (top), CpG islands and CpG island shores usually remain
unmethylated, allowing gene transcription. Additionally, DNA methyla-
tion within the gene bodies avoids spurious transcription initiation. In
cancer cells (bottom), by contrast, although both CpG islands and CpG
island shores may be strongly methylated, gene bodies lack this modi-
fication. As a result, the transcription of many genes gets blocked, and
aberrant transcription may occur from incorrect transcription start sites
(TSSs). (b) In normal cells (top), methylation of repetitive sequences
prevents genomic instability and spurious transcription initiation. More-
over, transposable elements cannot be activated in a methylated environ-
ment. In cancer cells (bottom), global hypomethylation triggers genomic
instability and aberrant transcription initiation. Concomitant activation of
transposons may lead to gene disruption. (from [Rodriguez-Paredes and
Esteller, 2011])
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island shores are methylated while methylation in the gene body
is lost (Figure 1.7). As a result, transcription of many genes is in-
hibited. Similarly, in normal cells, repetitive sequences are methy-
lated to prevent genomic instability and incorrect transcription ini-
tiation. In cancer cells, however, global hypomethylation leads to
genomic instability and aberrant transcriptional initiation. Aber-
rant hypomethylation can also lead to activation of oncogenes or to
the loss of imprinting as it is the case for IGF1 in Wilms’ tumor.
Hypermethylation in promoters can take place in both CpG island
promoters and non-CpG island promoters, which causes silencing.
Methylation of cytosine residues in CpG island promoters of TSGs
has been well-established. This is the case for RB1, CDKN2A,
VHL, MLH1 and BRCA1 inactivation. There are three main DNA
methyltransferases (DNMTs): DNTM1 maintains existing methy-
lation patterns after DNA replication, DNMT3A (mutated in AML)
and DNMT3B target previously unmethylated CpG islands. The
pharmacological inhibition of these enzymes provides novel oppor-
tunities for the therapy of human cancers. But the efficacy of these
drugs appears to be compromised by a lack a specificity.
2. Histones can undergo a variety of covalent modifications mostly
on their N terminal tails including acetylation, methylation, phos-
phorylation, ubiquitination, SUMOylation and ADP-ribosylation,
among others (Figure 1.9). The enzymes that put and remove chem-
ical moieties are many: histone acetyltransferases (HATs), deacety-
lases (HDACs), sirtuins, methyltransferases (HMTs) and demethy-
lases (HDMs), kinases, phosphatases, ubiquitin ligases, deubiquiti-
nases, SUMO ligases, proteases and so on. As well as genome-wide
studies are concerned, combinations of these modifications in a spe-
cific regions can form a ’histone code’, to a more ’open’ or ’close’
chromatin conformation and hence to the activation and repres-
sion of expression. H3K4me3 (Histone 3 lysin 4 tri-methylation),
H3K36me3 and H3K79me3, H4K20me and H2BK5me, and H3K9ac
(acetylation of H3K9) and H3K14ac result in gene activation, whereas
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H3K9me2, H3K9me3 and H3K27me3 lead to gene repression. In
embryonic stem (ES) cells, developmental genes poised for lineage-
specific activation or repression contain bivalent marks, which con-
sists of activating and repressing marks at the same time, H3K4me3
and H3K27me3. One of the most common histone modifications in
cancer are the global reduction of H4K20me3 and acetylation of
H4K16 along with DNA hypomethylation at repeat sequences. In
addition, there are many alterations of the enzymes related to his-
tone modifications (Figure 1.9). A recent publication has described
inactivating mutations in the histone methyltransferase SETD2 and
in the histone demethylase UTX and JARID1C in renal carcinomas.
Another example is the histone methyltransferase EZH2, a sub-
unit of the PRC2 and PRC3 complexes, which enhances prolifer-
ation and neoplastic transformation and is overexpressed in several
cancer types. Overexpression of the lincRNA HOTAIR in breast
tumors and metastases retargets PRC2 and alters the H3K27me3
landscape. Moreover, EZH2 expression is upregulated in many can-
cer tumors due to the genomic loss of miR-101. Histone modifica-
tions also are targeted by therapy. A class of related genes, HDACs,
is the target of approved therapies. HDAC inhibitors, vorinostat and
romidepsin used for the rare cutaneous T cell lymphoma among
other hematological malignancies [Rodriguez-Paredes and Esteller,
2011].
3. All families of chromatin remodelers have been tied to cancer. For
instance, BRG1 and BRM, the ATPase subunits of SWI/SNF com-
plexes, have been characterized as tumor suppressors and are si-
lenced in about 15-20% of primary non-small-cell lung cancers.
Mutations in SNF5, a subunit of the SWI/SNF remodeling com-
plex, have been observed in sporadic renal rhabdoid tumors and in
choroid plexus carcinomas, meduloblastomas and central primitive
neuroectodermal tumors [Portela and Esteller, 2010].
4. In addition to nucleosome positioning, histone variants have also
been related to cancer. For example, increased expression of MacroH2A
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is involved in senescence. Thus, lung tumors with highly expressed
MacroH2A have a better prognosis, with lower proliferation rates
and less frequent recurrence.
Techniques
Several techniques are used to study epigenetic modifications in normal
and cancer cells. Some of these profile epigenetic alterations in a genome-
wide manner, while others are centered in gene-specific alterations. High-
performance liquid chromatography (HPLC) and high-performance cap-
illary electrophoresis (HPCE) allow the quantification of the total amount
of 5-methycytosine. The study of DNA methylation at particular se-
quences has classically been studied using restriction enzymes that can
distinguish between methylated and unmethylated recognition sites. Newer
methods are based on the use of bisulphite treatment of DNA, which
changes unmethylated cytosines to uracil leaving methylated cytosines
unchanged. These methods can be coupled with PCR and sequencing
of candidate genes. Moreover they can also be combined with genomic
approaches in order to detect genome-wide DNA-methylation patterns,
for example, by using promoter microarrays or arbitrary primed PCR,
in which no prior sequence information is required for amplification. In
addition, there are techniques based on chromatin immunoprecipitation
(ChIP) with the ChIP-on-chip approach using antibodies against methyl-
CpG-binding domain proteins (MBDs) or using an antibody directly against
5-methylcytosine (methyl-DIP). Another way of assessing genome-wide
DNA-methylation patterns is by using gene-expression profiling microar-
rays comparing mRNA levels from cells before and after treatment with a
demethylating drug. However, this method yields a significant amount of
false positives, requiring confirmation with bisulphate genomic sequenc-
ing. The profiling of histone modification marks is typically studied by
ChIP using antibodies agains specific histone modifications. The im-
munoprecipitated DNA is then analyzed by PCR with specific primers to
investigate the presence of a candidate DNA sequence or on a microarray
chip (ChIP-on-chip) to profile an extensive map of histone modifications.
More recently ChIP is combined with ultrasequencing techniques (ChIP-
Seq) to obtain higher resolution and genome-wide chromatin occupancy
33
“main-gunes” — 2011/6/7 — 13:52 — page 34 — #46
Figure 1.8: Histone modification patterns in normal and cancer cells.
Histones can undergo diverse post-translational modifications mainly in
their protruding N-terminal tails and their C-terminal regions. In the right
combination, these modifications contribute to establishing the global and
local condensed/decondensed chromatin states that determine gene ex-
pression. Shown here are the main modifications of the four core histones
in normal cells. Since disruption of their normal patterns is related to
cancer, histone modifications are typically associated with the disease.
Ac, acetylation; Me, methylation; P, phosphorylation; Ub, ubiquitination.
(from [Rodriguez-Paredes and Esteller, 2011])
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Figure 1.9: Nucleosome positioning patterns. Nucleosome positioning
plays an important role in transcriptional regulation. Transcriptionally
active gene promoters possess a nucleosome-free region at the 5’ and
3’ untranslated region, providing space for the assembly and disassem-
bly of the transcription machinery. The loss of a nucleosome directly
upstream of the TSS is also necessary for gene activation, whereas the
occlusion of this position leads to transcription repression. DNA methy-
lation regulates transcription, and thus interferes with nucleosome posi-
tioning. Methylated DNA seems to be associated with ’closed’ chromatin
domains, where DNA is condensed into strictly positioned nucleosomes,
thereby impeding transcription. Conversely, unmethylated DNA is asso-
ciated with ’open’ chromatin domains, which allow transcription. (from
[Portela and Esteller, 2010])
35
“main-gunes” — 2011/6/7 — 13:52 — page 36 — #48
maps .
1.3.4 Non-coding RNAs
The human genome contains only ≈ 20, 000 protein-coding genes, repre-
senting less than 2% of the total genome, whereas a substantial fraction
of the human genome can be transcribed, yielding many short or long
noncoding RNAs (ncRNAs) with limited protein-coding capacity [Birney
et al., 2007]. Hence, it has been proposed that non-coding RNAs (ncR-
NAs) may be the missing piece in the cancer jigsaw puzzle. Many dif-
ferent classes of ncRNAs have been discovered, constituting, what some
biologists call, ’the dark matter’ of biology. Of all these types, in can-
cer studies, researchers have so far focused especially on two emerging
classes of ncRNAs, micro RNAs (miRNAs) and long intergenic ncRNAs
(lincRNAs).
miRNAs in Cancer
First discovered in 1993 by Victor Ambros, these small RNA sequences
are non-protein-coding. They are typically 20-22 nucleotides in length.
miRNAs are typically generated through a mechanism that starts with the
transcription of a long precursor RNA (pri-miRNA), which is then pro-
cessed to a second precursor (pre-miRNA) of 60-100 nucleotides [Croce,
2009]. Transported to the cytoplasm, pre-miRNAs are further processed
to mature miRNAs. miRNAs act by modulating the expression of target
genes through sequence complementarity between their seed sequence
and the seed-match present in the target mRNA, which inhibits the trans-
lation and reduces the stability of the mRNA, leading to decreased ex-
pression of the target protein. They have been found to regulate over
30% of mRNAs and have roles in fundamental processes such as devel-
opment, differentiation, cell proliferation, apoptosis and stress responses
and in a range of organisms, including C. elegans, plants, Drosophila
melanogaster and mammals including humans [Croce, 2009]. Over the
past few years, many miRNAs have been implicated in various human
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cancers. There are various possible mechanisms through which miR-
NAs could affect tumorigenesis (Figure 1.10) [Ventura and Jacks, 2009].
Overexpression, amplification, or loss of epigenetic silencing of a miRNA
gene that targets TSGs could lead to loss of the tumor suppressor acivity.
By contrast, the physical deletion or epigenetic silencing of an miRNA
that normally represses expression of oncogenes might lead to increased
protein expression and a gain of oncogenic potency. Mutations affect-
ing the sequence of the mature miRNA or the seed-match sequences of
target mRNAs could reduce or eliminate the inhibitory interaction be-
tween the two. Although only some of these potential mechanisms have
been documented in human cancers, over the past years various reports
have linked miRNAs to tumor development in one way or another. These
range from the identification of genomic and gene expression alterations
affecting miRNA genes in human cancers to studies in genetically engi-
neered mouse models of the disease. Taken together, the available data
provides a compelling case that alterations in miRNA-mRNA regulation
can promote tumor development.
The first evidence of alterations of miRNA genes and dysregulation of
miRNA gene expression in human disease came from studies in chronic
lymphocytic leukemia (CLL) [Calin et al., 2002b]. In this study, it was
shown that the loss of miR-15a and miR-16-1, observed in 70% of CLLs,
was the target of 13q14 deletion in CLL pathogenesis. The tumor suppres-
sor activity of miR-15a/16-1 is not limited to B cells. More than 50% of
human prostate cancers carry a deletion of 13q14. Subsequently, it was
shown that many miRNA genes are located in chromosomal regions that
are frequently involved in chromosomal alterations, such as deletions or
amplifications, in many types of human cancers. Another widely studied
tumor suppressor miRNA is the let-7 family. Discovered in C. elegans,
reduced expression of multiple members of the let-7 family is frequently
observed in lung cancers, where they correlate with poor prognosis. In
addition, various let-7 genes are located at chromosomal sites deleted
in a variety of human cancers. Functionally, let-7 represses members
of the Ras family of oncogenes as well as the oncogene HMGA2 and
even c-Myc itself [Roush and Slack, 2008]. An interesting example for a
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Figure 1.10: miRNAs can function as tumor suppressors and onco-
genes. (a) In normal tissues, proper miRNA transcription, processing and
binding to complementary sequences on the target mRNA results in the
repression of target-gene expression. (b) A reduction in or elimination
of miRNA levels can occur because of defects at any stage of miRNA
biogenesis (indicated by question marks) and ultimately leads to the inap-
propriate expression of the miRNA-target oncoprotein (purple squares).
The overall outcome might alter key cellular processes ultimately leading
to tumor formation. (c) The amplification/overexpression of a miRNA
that has an oncogenic role would lead to increased amounts of a miRNA,
which, later on, would eliminate the expression of a target TSG (pink).
Increased levels of mature miRNA might occur because of amplification
of the miRNA gene, a constitutively active promoter, increased efficiency
in miRNA processing or increased stability of the miRNA (indicated by
question marks). ORF, open reading frame. (from [Esquela-Kerscher and
Slack, 2006]) 38
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miRNA acting as an oncogene is miR-155, which is upregulated in several
hematopoietic malignancies and tumors of the breast, lung, and pancreas
[Kluiver et al., 2006]. Another notable member of the family of onco-
genic miRNAs is the miR-17-92 cluster in a chromosomal region that is
frequently amplified in a subset of human B cell lymphomas [Mendell,
2008]. Finally, recent studies have explored the regulation of miRNAs by
tumor suppressor genes. For example, p53 regulates many miRNAs. Re-
duced expression of some these targets have been detected in breast and
non-small cell lung cancer cell lines [He et al., 2007].
Techniques
Several methodologies have been adapted for profiling miRNA expres-
sion. They include northern blotting with radiolabeled probes, cloning,
quantitative PCR-based amplification of precursor or mature miRNAs,
serial analysis of gene expression (SAGE)-based techniques, bead-based
profiling methods and oligonucleotide microarrays. As can be expected,
NGS-based technologies also can be applied to miRNA profiling [Morin
et al., 2008].
Long ncRNAs in Cancer
Long ncRNAs are considered to be longer than 200 nucleotides, on the
basis of a convenient practical cut-off in RNA purification protocols that
excludes small RNAs. Figure 1.11 describes the functions of long ncR-
NAs detected so far. One class of long ncRNAs is long intergenic ncRNAs
(lincRNAs) [Guttman et al., 2009]. The structure of this type of ncRNAs
is surprisingly complex often overlapping with, or interspersed between,
multiple coding and non-coding transcripts. Although more than 3,000
human lincRNAs have been identified, less than 1% of these have been
characterized [Ponting et al., 2009]. Recent studies showed that in addi-
tion to their involvement in development, lincRNAs can also be misex-
pressed in solid tumors and leukemias [Calin et al., 2007]. Nonetheless,
the basis of their molecular mechanisms is still largely unknown. Sev-
eral lincRNAs can control gene expression by directly recruiting histone-
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modifying enzymes to chromatin [Ponting et al., 2009]. One such lin-
cRNA, HOTAIR, is highly expressed in breast cancer metastases and in
primary tumors predisposed to future metastases [Gupta et al., 2010].
Tsai and colleagues recently discovered that HOTAIR function as scaf-
fold for the polycomb repressive complex 2 (PRC2; comprised of histone
H3 lysine 27 methylase EZH2, SUZ12, and EED) and the LSD1 H3K4
demethylase complex and recruits both complexes to target genes to co-
ordinately alter several histone modifications and enforce gene silencing
[Tsai et al., 2010]. Moreover, enforced expression of HOTAIR can tar-
get PRC2 genome-wide to alter H3K27 methylation and gene expression
patterns, resulting in increased cancer invasiveness and metastasis in vivo
[Gupta et al., 2010]. In multivariate analyses with clinical and pathologic
risk factors, HOTAIR RNA can serve as a significant and independent
predictor of metastasis and death and loss of HOTAIR or PRC2 compo-
nents inhibits cancer invasiveness, indicating potentially direct roles for
lincRNAs in modulating cancer progression [Gupta et al., 2010]. Another
lincRNA relevant to cancer is ANRIL. It is antisense transcribed from the
tumor suppressor genes CDKN2B and CDKN2A, where ANRIL interacts
with CBX7 (a subunit of PRC1), resulting in heterochromatin formation
and gene silencing [Yap et al., 2010].
1.3.5 Transcriptomic Changes in mRNAs
Changes in expression are not a direct cause of the tumorigenic pheno-
type, but the result of the accumulative effect of all the alterations I have
covered in this chapter. Although it has long been known that tumor cells
express some genes at abnormal levels, the extent of such alterations was
not realised until the advent of high-throughput gene expression profil-
ing techniques such cDNA microarrays. With this technology, expression
levels of thousands of genes can be assessed at the same time. analysis of
data from microarrays showed that large numbers of genes are differen-
tially expressed in cancer cells. This fact and the regulatory complexity
underlying the level of expression of mRNAs makes high-throughput ex-
pression analysis extremely difficult. How should long lists of deregulated
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Figure 1.11: Functions of long ncRNAs. Mechanisms by which long
ncRNAs regulate local protein-coding gene expression at the level of
chromatin remodelling, transcriptional control and post-transcriptional
processing. (a) ncRNAs can recruit chromatin modifying complexes to
specific genomic loci to impart their catalytic activity. In this case, the
ncRNAs HOTAIR, Xist and RepA, or Kcnqot1 recruit the Polycomb com-
plex to the HoxD locus, the X chromosome, or the Kcnq1 domain, re-
spectively, where they trimethylate me3K27 of histone H3 to induce het-
erochromatin formation and repress gene expression. (b) ncRNAs can
regulate the transcriptional process through a range of mechanisms. ncR-
NAs tethered to the cyclin D1 gene recruit the RNA binding protein TLS
to modulate the histone acetyltransferase activity of CREB binding pro-
tein (CBP) and p300 to repress gene transcription. (c) An ultraconserved
enhancer is transcribed as a long ncRNA, Evf2, which subsequently acts
as a co-activator to the transcription factor DLX2, to regulate the Dlx6
gene transcription. (d) A ncRNA transcribed from the DHFR minor pro-
moter in humans can form a triplex at the major promoter to occlude
the binding of the general transcription factor TFIID, and thereby silence
DHFR gene expression. (e) An antisense ncRNA can mask the 5’ splice
site of the zinc finger homeobox mRNA Zeb2 from the spliceosome, re-
sulting in intron retention. The translation machinery can then recognize
and bind an internal ribosome entry site (IRES) in the retained intron, re-
sulting in efficient Zeb2 translation and expression. (from [Mercer et al.,
2009])
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genes be interpreted? How should one decide which of the transcription-
ally deregulated genes are causally implicated in cancer?
One suggestion has come from studies using the concept of ’gene
signature’. Instead of a single gene, tumorigenic phenotypes can be ex-
plained by the signature defined by the expression level of a list of genes.
To identify groups of genes that change in expression, ’unsupervised meth-
ods’ have proved very useful. Without any a priori information, these
methods can help discover patterns in the data that cannot be extracted
by eye. For example, these methods led to the characterization of pre-
viously unknown, but clinically significant subtypes of cancer in breast
cancer, B-cell lymphoma, Burkitt’s lymphoma, prostate cancer and lung
cancer. In addition to mRNA expression, miRNA expression informa-
tion has also been proven to be helpful in dissecting cancer. There are
also other methods used in expression analysis making use of ’supervised
methods’. Using existing biological information as a guide, this approach
has been successfully used to predict recurrence, metastasis, outcome, re-
sponse to drug, etc.
Another way to extract useful information from microarray data is the
so called ’module analysis’. A seminal study is the module map [Segal
et al., 2004]. This study presented an integrative analysis of a large num-
ber of microarrays over many tumor types. Defining expression profiles
of different tumors as a combination of activated and deactivated modules
(sets of genes), the detected modules specific to particular types of cancer,
as well as those that are shared across a diverse set of cancer types [Segal
et al., 2004]. Another preeminent work made use of ’molecular concepts’
1.12 [Rhodes et al., 2007b]; sets of biologically related genes coming
from the Oncomine database [Rhodes et al., 2007a]. The gene signatures
were obtained using a method called COPA (cancer outlier profile anal-
ysis). This method was developed to identify ’outlier’ gene sets even if
their expression level is low or a small number of samples show over-
expression. They applied this method to prostate cancer and generated an
integrative model of progression [Tomlins et al., 2007].
Accumulation of large amounts of expression data prompted the gen-
eration of public databases such as the NCBI’s Gene Expression Omnibus
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Figure 1.12: Molecular concepts. (Upper-most panel) Genes correlating
with progression from benign prostate epithelium to metastatic prostate
cancer (Met) were identified. Columns and rows represent individual ar-
rays and genes. Red, blue and gray indicate relative overexpression, un-
derexpression and excluded, respectively. (Middle panel) Network view
of the molecular concept analysis of the ’overexpressed during progres-
sion’ (left) or ’underexpressed during progression’ (right). Each node
represents a molecular concept with a size proportional to the number
of genes in the concept. Each edge represents a statistically significant
enrichment. The most enriched concept of each type in the progression
signature is indicated by a thick edge. (Lower-most panel) The enriched
concepts was used to develop a molecular concept model of prostate can-
cer progression. (from [Tomlins et al., 2005a])
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[Barrett et al., 2011b], the European Bioinformatics Institute’s ArrayEx-
press [Brazma et al., 2003], the Stanford Microarray Database [Hubble
et al., 2009] and Oncomine [Rhodes et al., 2007a]. The first three of these
mainly serve as data storage platforms while providing some data analy-
sis options. On the other hand, Oncomine is designed to be a data-mining
tool specific to cancer-related expression analysis. Such repositories make
it possible to compare different microarray results.
1.3.6 Cancer in the Sequencing Era
Early Sequencing Studies
The sequencing of human genome lead to the proposal that in order to
detect the full compendium of mutations in individual cancers, systematic
sequencing was crucial [Futreal et al., 2001]. However, after the first
sequencing efforts, it became evident that the classification of somatic
mutations into drivers and passengers is difficult. Hence, even if cancer
samples had been sequenced, the analysis of the data would not have been
easy, but would have required complex bioinformatic methods. Since
sequencing was expensive then, the first studies focused on specific gene
families. One usual suspect was the family of protein kinases, which
constitute good pharmacological targets. Samples from different types
of human cancers were screened for mutations in kinase genes [Futreal
et al., 2004, Stephens et al., 2005, Davies et al., 2005, Bardelli et al.,
2003]. Soon enough the search space for somatic mutations was increased
to encompass all the exons of protein-coding genes [McLendon et al.,
2008, Ding et al., 2008, Greenman et al., 2007, Jones et al., 2008, Parsons
et al., 2008, Sjoblom et al., 2006, Wood et al., 2007, van Haaften et al.,
2009, Morin et al., 2010, Jones et al., 2010, Dalgliesh et al., 2010, Parsons
et al., 2011, Verhaak et al., 2010, Taylor et al., 2010]. Typically, these
studies looked for mutations in the ≈ 20, 000 protein-coding genes in
10-20 examples of a particular cancer class. Several insights have been
provided by these early studies. Following are some of the important
results obtained from these studies:
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a. Mutations in histone modification enzymes: A number of genes
involved in histone modification were found to be mutated in dif-
ferent types of cancers. The detection of UTX mutations prevalent
in multiple myeloma and also in esophageal squamous cell carci-
nomas and renal cell carcinomas indicates that genetic mechanisms
may underlie epigenetic deregulation in cancers [van Haaften et al.,
2009]. This idea was supported by the discovery of mutations
in EZH2 in GCB subtype of diffuse large B-cell lymphomas and
follicular lymphomas [Morin et al., 2010]. Other histone modify-
ing genes, SETD2 (a histone H3 lysine 36 methyltransferase) and
JARID1C (a histone H3 lysine 4 demethylase) were found to be mu-
tated in sequencing studies in clear cell renal cell carcinoma [Dal-
gliesh et al., 2010] and ARID1A in clear cell ovarian cell carcinoma
[Jones et al., 2010]. ARID1A is also mutated in medulloblastoma
along with H3K4 trimethylases of MLL2 and MLL3 [Parsons et al.,
2011]. IDH1 (isocytrate dehydrogenase 1) mutations might also be
included here due to its proposed effect on the protein activity of
JmjC histone demethylases (see below).
b. The metabolism connection: After the discovery of mutations af-
fecting IDH1, mutations in the same gene were also detected in
acute myeloid leukemia [Mardis et al., 2009] while both IDH1
and IDH2 mutations were found in myeloproliferative neoplasms
[Green and Beer, 2010]. These discoveries supported the case for
systematic and comprehensive mutational screens in cancer, but
maybe more importantly, drew attention to a century-old concept of
metabolic alterations in cancer. Over the past years, succinate dehy-
drogenase (SDH) and fumarate hydratase (FH), were identified as
bona fide tumor suppressors [King et al., 2006]. However, unlike
SDH and FH, IDH1 does not follow Knudson’s two-hit hypothe-
sis. IDH1 and IDH2 mutants lose their original function, which
results in the production of 2-hydroxyglutarate instead of alpha-
ketoglutarate (Figure 1.13) [Dang et al., 2009, Ward et al., 2010].
The oncogenic effect of this gain-of-function mutation is not known
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exactly. It is proposed that 2-hydroxyglutarate inhibits the activity
of many different enzymes by competing with alpha-ketoglutarate
binding [Frezza et al., 2010]. The enzymes supposedly affected
are JmjC histone demethylases, EglN3 and the transcription factor
HIF-1 (Figure 1.13).
c. Identification of subtypes: In addition to new oncogenic alter-
ations discovered, comprehensive genomic analysis of glioblastoma
led to the characterization of already known cancer subtypes and
the identification of new ones [Verhaak et al., 2010]. The Cancer
Genome Atlas (TCGA) established four clinically relevant glioblas-
toma subtypes namely proneural, neural, classical and mesenchy-
mal. In addition, they characterized the classical, mesenchymal,
and proneural subtypes by aberrations and gene expression of EGFR,
NF1, and PDGFRA/IDH1, respectively. Moreover, in another TCGA
publication it was shown that the proneural subtype is related to a
CpG island-methylator phenotype (CIMP), which is more preva-
lent among lower-grade gliomas with distinctive copy-number al-
terations, and is tightly associated with IDH1 somatic mutations
[Noushmehr et al., 2010]. Genomic analysis paid off in the case of
prostate cancer too. Taylor et al. identified distinct subgroups with
differing risk of relapse after prostatectomy [Taylor et al., 2010].
Essentially what they found was a group of prostate tumors with
extensive DNA copy-number alterations that had a much shorter
time to recurrence than other tumors. Additionally, another group
of prostate tumors that were diploid without any major DNA copy-
number alterations were largely recurrence free during the 5 year
period of clinical follow-up. It is possible then to envision an ar-
ray CGH-based test being able to pinpoint not only the patients
likely to recur quickly but quite possibly the ones that do not even
need surgery. One more step towards personalized medicine (Fig-
ure 1.14).
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Figure 1.13: The metabolism connection. SDH, SDHAF2 and FH were
the first tumor suppressors identified related to metabolism. SDH oxi-
dizes succinate to fumarate and FH performs the hydration of fumarate
to malate. Mutations of these genes result in the accumulation of their
substrates which leads to the stabilization of HIF-1, a key TF in the cel-
lular response to hypoxia, including the upregulation of glucose transport
and glycolysis. Their dysfunction may also lead to the generation of ROS
leading to the stabilization of HIF-1 as well as the inhibition of EglN3
(PHD3) mediated apoptosis. Other enzymes use alpha-ketoglutarate as
a substrate, with succinate as a product. These include the JmjC his-
tone demethylases (JHDMs) which remove methyl groups from the his-
tones H3 and H4 altering chromatin structure. Finally, the last addition
to this metabolic gang was IDH1/2, NADP+-dependant enzymes impor-
tant for the production of alpha-ketoglutarate and NADPH playing a vital
role against reactive oxygen species. It was suggested that IDH1 might
undergo gain-of-function mutations and produce R(-)-2-hydroxyglutarate
(D-2-HG). However, the relevance of this finding is unclear and that IDH
mutations might affect the activation of HIF1 in a manner similar to SDH
and FH genes, by decrease ing the levels of alpha-ketoglutarate, the PHD
substrate. (from [Bayley and Devilee, 2010])
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Figure 1.14: Almost personalized medicine for prostate cancer. a) An
implementation of an array CGH test to stratify newly diagnosed prostate
cancer patients into three subgroups, the subgroup in which tumors show
extensive DNA copy-number alterations and is highly enriched for pa-
tients who will have recurrences within five years, the subgroup that have
tumors without DNA copy-number alterations and may not even require
surgery, and the remaining subgroup that would probably need surgery but
are not at high risk of relapse. a) Testing of adjuvant treatments for high
risk patients identified by array CGH. Priority would be given to inhibitors
of cancer pathways identified by genomic analysis. (from [Trotman and
Powers, 2010])
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Sequencing More
During the last decade, there have been major advances in our under-
standing of genome based on capillary-based DNA sequencing (’first-
generation sequencing’, also known as Sanger sequencing). This technol-
ogy provided the ability to sequence the human genome sequence. With
the arrival of second-generation sequencing technologies, cancer research
has been transformed extensively. However, still, there are particular chal-
lenges for the analysis of cancer genomes:
a. Characteristics of cancer samples: Cancer samples differ in their
quantity, quality and purity. The quantity of nucleic acids from
specimens may be too few for second-generation sequencing tech-
nologies. An alternative is whole-genome amplification but this
method does not preserve genome structure. The quality of the nu-
cleic acids may also pose a problem. Most cancer specimens are
formalin-fixed and paraffin-embedded (FFPE). analysis of FFPE
samples requires special experimental and computational methods.
Another confounding factor for quality is biological. Cancerous tis-
sue typically contains substantial fractions of necrotic or apoptotic
cells. Moreover heterogeneity within the cancer cells is another big
problem. Therefore, ideally one needs to achieve many-fold cover-
age to overcome these problems.
a. Structural variability in cancer samples: Cancer genomes vary
substantially in their sequence and structure compared to normal
genomes and among themselves. One problem is difference in mu-
tation frequency. Hence the analysis of mutations must be adjusted
for the background mutation rate, the ploidy and the purity of each
sample and the copy number at each region. Another problem is
our lack of understanding of structural variability in our genome.
One needs a ’matched normal’ cancer genome sequence to filter
individual-specific alterations.
Second-generation sequencing can be applied to cancer samples in
various ways. These vary by the type of input material (for example,
49
“main-gunes” — 2011/6/7 — 13:52 — page 50 — #62
DNA, RNA or chromatin), the proportion of the genome targeted (the
whole genome, transcriptome or a subset of genes) and the type of varia-
tion studied (structural change, point mutation, gene expression or chro-
mosomal conformation) (Figure 1.15). With the use of technologies that
extract subsets of DNA sequences from the whole genome (Figure 1.16)
[Mamanova et al., 2010], some focus on coding sequences of protein-
coding genes [Harbour et al., 2010, Varela et al., 2011, Jiao et al., 2011].
Sequence extraction can be used to isolate RNAs to be sequenced af-
terwards. This method was used to analyze the transcriptomes of many
hundreds of cancers. With sufficiently high levels of mRNA, this method
can report rearrangements that are transcribed [Maher et al., 2009, Morin
et al., 2010, Wiegand et al., 2010]. However, these approaches generally
miss the abnormalities of noncoding regions.
The list of chromatin-associated mutated genes grew with these stud-
ies. Chromatin-remodeling proteins MEN1, DAXX, and ATRX were
found mutated in pancreatic neuroendocrine tumors [Jiao et al., 2011],
a chromatin-remodeling complex subunit, ARID1A in endometriosis as-
sociated ovarian tumors [Wiegand et al., 2010], a SWI/SNF complex gene
PBRM1 in renal cell clear cell carcinoma [Varela et al., 2011] and EZH2
in GCB subtype of diffuse large B-cell lymphomas and follicular lym-
phomas [Morin et al., 2010].
The major potential of transcriptome sequencing for cancer is the dis-
covery of chromosomal rearrangements. Until recently it was thought
that chromosomal translocations were rare in epithelial tumors and found
only in haematological malignancies in which they could be observed
with cytogenetic methods. However, the discoveries of TMPRSS2-ERG
translocations in prostate carcinoma [Tomlins et al., 2005b], EML4-ALK
translocations in non-small cell lung carcinoma [Soda et al., 2007] and
recurrent translocations of BRAF and CRAF genes in prostate carcino-
mas [Palanisamy et al., 2010] among others [Stephens et al., 2009] have
changed that view. Similar to point mutations, chromosomal rearrange-
ments also vary greatly between tumor specimens (Figure 1.17).
Finally, the most complete genomic analysis of a tumor can be done
using whole genome sequencing. There are already some cancer sam-
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Figure 1.15: Types of genome alterations that can be detected by NGS
Sequenced fragments are depicted as bars with coloured tips representing
the sequenced ends and the unsequenced portion of the fragment in grey.
Reads are aligned to the reference genome (chromosome 1 in this exam-
ple). The colours of the sequenced ends show where they align to. Differ-
ent types of genomic alterations can be detected, from left to right: point
mutations (in this example A to C) and small insertions and deletions (in-
dels) (in this example a deletion shown by a dashed line) are detected by
identifying multiple reads that show non-reference sequence; changes in
sequencing depth (relative to a normal control) are used to identify copy
number changes (shaded boxes represent absent or decreased reads in the
tumor sample); paired-ends that map to different genomic loci (in this
case, chromosome 5) are evidence of rearrangements; and sequences that
map to non-human sequences are evidence for the potential presence of
genomic material from pathogens. (from [Meyerson et al., 2010])
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Figure 1.16: Sequence capture. A schematic diagram of hybrid selection
to capture specific regions of the genome from tumor DNA (left panel,
blue) and normal DNA (right panel, red). DNA from the starting ma-
terial (the ’pond’) is sheared and hybridized to oligonucleotides that are
specific for the regions of interest. The baits have a tag that allows them
to be isolated. The captured DNA is eluted, prepared into sequencing
libraries, sequenced and aligned to the bait sequences. Because this tech-
nique allows greater depth of coverage for the regions of interest, somatic
mutations in the tumor DNA can be detected from admixed populations
containing tumor and normal DNA-derived reads. (from [Meyerson et al.,
2010])
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ples that have been analyzed with this technique [Ding et al., 2010a, Ley
et al., 2008, Mardis et al., 2009, Pleasance et al., 2010a, Pleasance et al.,
2010b, Lee et al., 2010, Shah et al., 2009]. In this strategy, genomic DNA
from a cancer and from normal tissue of the same person is randomly
fragmented and hundreds of millions of fragments are sequenced. This
strategy can generate almost complete catalogs of somatic mutation for
individual cancers revealing all classes of somatic changes (base substi-
tutions, indels, rearrangements, copy number changes, and even poten-
tially epigenetic alterations) in all sectors of the genome (exons, introns,
and intergenic regions). The biggest advantage is the detection of so-
matic mutations of non-coding regions, including promoters, enhancers,
introns and non-coding RNAs (including microRNAs), as well as unan-
notated regions and repetitive elements [Huang et al., 2010]. However,
these methods require the greatest amount of sequencing, it is the most
costly. An alternative low-cost approach is shotgun sequencing with a
coverage less than 30-fold. This is sufficient to detect somatic rearrange-
ments [Campbell et al., 2008, Stephens et al., 2009] and copy-number
alterations [Campbell et al., 2008].
1.3.7 Oncogenomic Projects and Recourses
The International Cancer Genome Consortium (ICGC)
The International Cancer Genome Consortium [Hudson et al., 2010], launched
in 2008, is a collaboration designed to produce high-quality genomic data
in multiple cancer types. This international consortium has three primary
goals:
a. The coordination of projects to generate comprehensive catalogues
of somatic mutations in tumors in 50 different cancer types and/or
subtypes which are of global clinical and societal significance.
b. To generate transcriptomic and epigenomic datasets from the same
tumors.
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Figure 1.17: Somatic rearrangements observed in six breast cancer
samples (a) Genome-wide Circos plots of somatic rearrangements. An
ideogram of a normal karyotype is shown in the outer ring. A copy num-
ber plot is represented by the blue line shown inner to the chromosome
ideogram. Within the inner ring each green line denotes an intrachro-
mosomal rearrangement and each purple line an interchromosomal re-
arrangement. ER, oestrogen receptor; PR, progesterone receptor. (b)
The prevalence of rearrangement architectures in individual breast can-
cers: deletion (dark blue), tandem duplication (red), inverted orientation
(green), interchromosomal rearrangements (light blue), rearrangements
within amplified regions (orange). (c) Extent of overlapping microho-
mology at rearrangement breakpoints. The number of base pairs of mi-
crohomology is plotted on the horizontal axis. (from [Stephens et al.,
2009])
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Figure 1.18: Sequence capture. Schema representing a method to em-
ploy transcriptome sequencing to identify chimeric transcripts. ’Long
read’ sequences compared with the reference database are classified as
’Mapping’, ’Partially Aligned’, and ’Non-Mapping’ reads. Partially
aligning reads are considered putative chimeras and are categorized as
inter- or intra-chromosomal chimeras. Integration with short read se-
quence data is utilized for short-listing candidate chimeras and assessing
the depth of coverage spanning the fusion junction. (from [Maher et al.,
2009])
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c. To ensure that these data are available to the research community at
large as quickly as possible, and with minimal restrictions.
The Cancer Genome Atlas
The Cancer Genome Atlas (http://tcga.cancer.gov/) is a colloboration be-
tween the United States National Cancer Institute and the National Hu-
man Genome Research Institute. The goal of the project is to increase un-
derstanding of cancer through the systematic use of various genome-wide
technologies including sequencing technologies. The Cancer Genome At-
las began in 2006 as a three-year pilot project which undertook analysis
of three tumor types, brain (glioblastoma multiforme), lung (squamous
carcinoma), and ovarian (serous cystadenocarcinoma). After the success
of the pilot project, TCGA program has been extended to include 20 more
tumor types. TCGA also became a part of the ICGC.
1.3.8 Oncogenomic Databases
With the accumulation of high-throughout cancer data, many databases
have been generated as warehouses for this data. Following are some of
these oncogenomic resouces already available.
Gene Expression Omnibus (GEO)
Established at the National Center for Biotechnology Information, GEO
is a public data repository which contains ≈ 20, 000 studies including
microarray, NGS and other forms of high-throughput functional genomic
data [Barrett et al., 2011a]. First began as an expression database, GEO
currently also contains genome-wide DNA binding/accupancy profiling,
methylation profiling and genome variation profiling data. The database
is not specific to any species or subject such as cancer. GEO does not
provide any meta-analysis of its data sets although it organizes curated
’Datasets’ extracting data from data sets compatible with each other, for
example, from the same expression microarray platform.
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ArrayExpress
ArrayExpress is a public database that consists of three components [Parkin-
son et al., 2011]: the ArrayExpress Repository–a public archive of func-
tional genomics experiments and related supporting data; the ArrayEx-
press Warehouse–a database of gene expression profiles and other bio-
measurements and the ArrayExpress Atlas–a summary database and meta-
analytical tool of ranked gene expression across multiple experiments and
different biological conditions. One of the three recommended reposito-
ries for publication-related genomics data, it contains data from over 6000
experiments studies. The majority of the data are array-based, but other
data types are included, most recently NGS transcriptomics and epige-
netic data. The Warehouse and Atlas function as a tool in which users
can query for differentially expressed genes by gene names and proper-
ties, experimental conditions and sample properties, or a combination of
both. Like GEO ArrayExpress contains data for various species and under
many different conditions.
Progenetix
Progenetix is a database that provides data about copy number abnormal-
ities in human cancer obtained with Comparative Genomic Hybridiza-
tion (CGH) and array CGH experiments [Baudis and Cleary, 2001]. As a
curated database, it collects genomic gain/loss information of individual
cancer cases published in peer reviewed journals. All cancer cases are an-
notated with disease and location terms from International Classification
of Disease from WHO (ICD) enabling the integration of different data
sets sharing clinical terms. However this database provides results at the
level of individual cancer cases only.
Oncomine
Oncomine is a web-based tool that allows researchers to mine a large set
of published functional genomics data from cancer experiments [Rhodes
et al., 2007a]. Currently it contains microarray expression and genomic
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aberration data that is clinically annotated. Oncomine provides a couple
of functionalities to perform a set of analysis including but not limited
to enrichment analysis and meta-analysis. The major drawback of On-
comine is that most of the interesting features are available only in the
commercial version.
Catalogue of Somatic Mutations — COSMIC
COSMIC is a database designed to store and display somatic mutation
information and contains information related to human cancers [Forbes
et al., 2011]. In addition to detailed information about mutations, it also
includes samples which have been found to be negative for mutations
during screening therefore enables frequency data to be calculated for
mutations in different genes in different cancer types. Mutation data and
associated information is extracted from literature.
In spite of all these databases/web-based tools, there is still a need
for an integrative oncogenomics resource. Because some of these such
as GEO and ArrayExpress mainly serve as public repositories without
providing any analysis options. Some, as in the case of Progenetix and
COSMIC, focus on a specific type of alteration. Oncomine, on the other
hand, is a cancer mining tool with useful analysis methods. However, it
does not attempt to perform integrative analysis and visualization of the
data sets it contains. Therefore, cancer research society needs an integra-
tive oncogenomic tool that ideally should provide analysis results at the
level of individual studies as well as results obtained by pooling informa-
tion coming from these studies. It should implement statistical methods
to be able to perform such analyses. It should also bring together data
from many different types of alterations that take place in cancer. Finally,
it should offer powerful visual representation of the results. This last fea-
ture may not seem as important but it is indispensable for oncogenomic
studies which usually yield a large number of results making interpreta-
tion the most difficult part of the analysis.
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In light of the information provided in the previous introductory ch-
pater, the objectives of this thesis can be listed as follows:
1. to design an integrative approach for the analysis of high-throughput
functional genomics data for the study of human cancer. This ob-
jective can be divided to smaller objectives:
(a) to collect and annotate data related to different types of alter-
ations that take place in cancer
(b) to develop statistical methods to perform different types of
integrative statistical methods
(c) to design intuitive and powerful visualization methods to in-
crease interpretability
2. to devise a methodology based on sample-level enrichment analysis
to detect clinically relevant patient subgroups in oncogenomic data
3. to apply the approach developed in the previous objective to as-
sess the prognostic power of a senescence-related gene signature in
multiple cancer types
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This chapter is about IntOGen, a collaborative project carried out in the
Biomedical Genomics group. It brings together and analyzes a large
amount of oncogenomic data from transcriptional profiling, copy number
aberration and mutational analysis studies. It was realized by a research
team consisting of professional computer scientists, computational biol-
ogist and a statistician. The system has three components: ’the oncoge-
nomic data’, ’the pipeline’ and ’the web service’. The tasks were del-
egated to people with appropriate backgrounds. My main involvement
was in the data part. I collected, organized, preprocessed and annotated
the oncogenomic data. The web service was designed and implemented
by Jordi Deu Pons. Anna Kedzierska, Christian Perez and I designed the
pipeline to decide on the methods to be included while Christian Perez
implemented it. Each of these tasks are crucial for the final results. The
separation of the work to technical and biological parts enabled me to fo-
cus on the cancer data sets. Since our audience is biologists, it is very
important we keep good quality and relevant data sets in IntOGen. The
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Cancer is a complex disease that affects numerous tissue types. Although the steps a normal 
cell undergoes during transformation are broadly similar1, the oncogenic alterations 
underlying the process are many both in terms of the genes affected and the type of  
alteration2. Therefore, recent technologies for genome-wide surveys of tumors, such as 
mRNA expression arrays, comparative genomics hybridization arrays (aCGH), exon 
resequencing, and epigenetic methods, while offering a wealth of data, do so from only one 
vantage point. The necessity of a multi-perspective analysis of cancer has been elucidated in 
a number of recent compelling studies that have combined data from complementary 
experimental techniques in human glioblastomas and pancreatic tumors3-5. The integration of 
different classes of data and subsequent pathway analysis allowed a revelatory insight to the 
core pathways involved in oncogenesis in these tumors. 
 
While these projects have suggested a blueprint for modern molecular cancer research, there 
are numerous oncogenomic studies, both past and present, which have availed of a single 
experimental method for surveying tumor cells. The data from many of these studies are 
available in public repositories such as the Gene Expression Omnibus (GEO)6, Array 
Express7, COSMIC8, the Cancer Chromosomes database9 and Progenetix10, amongst others. 
In fact a number of projects already collate and analyze multiple datasets from cancer gene 
expression studies11,12 and genomic rearrangements13,14, or heterogeneous data types for 
particular tumor types15,16. However, the vast majority of cancer databases focus on a specific 
tumor type, provide access to a single class of data, or are not designed to analyze different 
data classes in an integrated manner.  
 
We have addressed these issues in IntOGen, which integrates oncogenomic data from 
expression, cytogenetic, and sequencing studies for multiple tumor types, in an integrated 
fashion on a single platform. A specifically designed statistical framework facilitates 
comparisons of different data classes in particular tumors, and between tumor types. In 
addition, IntOGen will allow analysis of the types of data that are being generated by the 
Cancer Genome Atlas Research Network3 and the International Cancer Genome 
Consortium17 by facilitating both gene-centric and pathway-centric study of these 
multidimensional oncogenomic data. Furthermore, IntOGen allows integration and 
retrospective interrogation of much of the wealth of functional genomic data that have been 
generated by the cancer research community over the past decade or so. 
 
IntOGen system is flexible and is designed to be updated regularly, when new experiments or 





IntOGen (Integrative OncoGenomics) is a novel framework to enable the study of cancer 
alterations from a global perspective (Supplementary Figure 1). It allows the collation, 
integration, analysis, data-mining and visualization of oncogenomic data. IntOGen is designed 
to be an updatable, flexible, extensible and efficient system for integrative oncogenomics 
analysis and visualization. 
 
IntOGen consists of three main components: 1) Data, including oncogenomic data and 
biological modules. 2) Statistical methods for analysis and integration of the data. The 
statistical methodologies have been implemented with the objective of identifying driver genes 
and modules significantly altered in different tumor types. 3) Visualization methods to explore 
the results in intuitive and efficient ways. We have developed two complementary 
visualization systems, i) A publicly accessible web system (www.intogen.org) which allows an 
easy and efficient access to IntOGen results and ii) A standalone Java application, GiTools, 
which permits more flexible and sophisticated navigation of IntOGen data and results 
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(manuscript in preparation). GiTools is able to visualize and navigate over color matrices 
showing results for a number of cancer types and a number of genes or modules. GiTools 





Supplementary Figure 1. Conceptual schema. IntOGen consists of three main components: 1) Data, 
including oncogenomic data and biological modules. 2) Statistical methods for analysis and integration 
of the data. 3) Visualization methods to explore the results in intuitive and efficient ways 
(www.intogen.org and GiTools). 
 
 
Oncogenomic Data collation and annotation 
 
Oncogenomic data comprise a collation of independent experiments that analyze different 
types of alterations (such as copy number alterations, point mutations, differential gene 
expression or methylation aberrations) in a number of cancer samples. The current version of 
IntOGen includes transcriptomic alterations, genomic gains and losses, and somatic mutation 
information (Supplementary Table 1). However, the system has been designed to incorporate 
other types of alterations, when they become available, such as epigenomic alterations and 
proteomic data. 
 
Supplementary Table 1. Data sources and number of experiments, assays and tumor types 



























• Sanger Cancer 
Genome Project 
• TCGA 
731 20493 72 337 
Mutations • Cosmic - - 33 78 
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There are several important considerations as to how we store and structure the data in order 
to take full advantage of the information therein. A key aspect for the utility of the collated data 
for integrative analysis is correct annotation of the type of cancer using a structured 
vocabulary (see Methods for details). We annotate all samples manually according to the 
International Classification of Disease18, ICD-10 and ICD-O terms, which specify the 
topography and morphology of the tumor. This ensures that we can combine and compare 
the results for different experiments that have the same disease classification. All 
experiments are additionally annotated with information about the original authors, publication 
and platform used. 
 
All experiments collated and shown in IntOGen analyze alterations in cancer cells compared 
to normal cells (normal cells of the same tissue in the case of expression), in order to identify 
which are the main changes involved in the development of different cancer types. However, 
it is important to note that all the methods developed under the IntOGen framework are 
designed to be useful in any other comparison, for example, metastasis versus primary tumor, 
or responders to a particular drug versus non-responders. 
 
Cancer related genes identification 
 
During the process of tumorigenesis large numbers of alterations accumulate in cancer cells 
as a result of repeated rounds of cell division often accompanied by genome instability. 
Studies utilizing techniques for high-throughput oncogenomic analyses are able to highlight 
panels of genes that are altered in cancer. However, these candidate cancer genes must then 
be scrutinised to reveal whether they contribute to oncogenesis or are passenger alterations. 
To distinguish driver from passenger alterations we can apply statistical methodologies based 
on the rationale that driver alterations are found in more samples than expected by chance, 
while this is not the case of passenger alterations. Thus, the first step in the IntOGen analysis 
pipeline is to assess the significance of each alteration in each experiment independently; this 
results in a p-value per gene and per experiment (Figure 1A). Currently we use a binomial 
approach to assess (see Methods) if a particular gene is significantly amplified, deleted, over-
expressed or under-expressed in a particular experiment. Note that this step could be done 
using different methods depending on the type of data analyzed. 
 
Whenever several datasets related to a specific subject are gathered, a natural question that 
arises is whether the combined evidence among them supports a particular hypothesis. 
Therefore, after computing p-values for alteration events seen in individual studies, we need 
to integrate the information from different experiments analyzing the same cancer 
type/subtype. Therefore, annotation of the experiments using the ICD terms is crucial for this 
combination. Pooling evidence from multiple studies provides an insight into the patterns 
shared among experiments with the same annotation. However the heterogeneous nature of 
the data makes it difficult to compare experiments. For example, we included microarray data 
using different platforms or even different methodologies (single-channel vs. dual-channel). 
Therefore, the individual experiments are not compatible for producing a single combined 
data set to do a second meta-analysis directly from data. However, we can produce a 
combined test of significance of alteration events across a set of experiments with the same 
clinical annotation19. Many different methods have been proposed to combine evidence from 
different studies. We have implemented the weighted Z-method, which has shown to be 
preferable20 for this purpose. Since different studies differ substantially with respect to sample 
size, the weighting scheme employed depends on the number of samples in the experiment, 
thus weighting higher those experiments that analyze more samples (see Methods).  
 
Identification of modules significantly altered in cancer 
 
Analysis at the level of individual genes is very informative but does not capture the full 
complexity of biological systems. For that we need to analyze the contribution of biological 
modules to cancer. We define a Biological Module as a set of genes that have a common 
biological property. For example all genes involved in the cell cycle are part of the Module 
“Cell Cycle” and all genes regulated by the transcription factor E2F4 are part of the Module 
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“regulated by E2F4”. In this case, we want to assess if a set of genes that forms a particular 
module is altered in a particular experiment more than expected by chance (see Methods). 
Next we combine different experiments that analyze the same tumor type in order to identify 
modules that are consistently altered. The combination is done with the weighted Z-method 




Supplementary Figure 2. Identifying driver modules. Once we have a p-value per experiment (after 
step 1 in figure 1A) we group the genes in modules and perform an enrichment test for each module. 
Those modules that contain a higher number of genes altered than expected by chance will have a 
significant p-value (e.g. module 1 in the figure). The next step is the combination of experiments that 
analyze the same types of cancer (same ICD term) in order to obtain a combined p-value. 
 
The main types of modules we are initially interested in are: Functional Modules, such as 
Gene Ontology terms or KEGG pathways, which aid our understanding of the functional 
patterns of the genes involved in cancer, Regulatory Modules, which allow us to study the 
regulatory patterns important in cancer development, and Cancer Related Modules 
(OncoModules), which highlight similarities in alteration patterns among different types of 
cancer. However, the IntOGen framework is designed to include any type of biological 
modules, and a user can include his/her own modules and study them in the context of all of 
the data in IntOGen. 
 
Analysis of TCGA glioblastoma expression data21 using IntOGen methodology successfully 





All results obtained with IntOGen analysis are displayed in www.intogen.org. This web 
interface is designed to be a discovery tool for cancer researchers. It includes a number of 
useful options for the user (Supplementary Table 2 and Supplementary tutorials 1 to 6). 
Firstly, cancer researchers interested in a particular tumor type are able to browse the 
different experiments that analyze samples of this cancer type, to find out which are the most 
frequently altered genes in those samples, and the most significant modules. It is also 
possible to explore the results of individual experiments and to combine a group of 
experiments that the user selects based on his/her knowledge or interests. Secondly, 
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molecular biologists working on a particular gene are able to see if their gene of interest is 
significantly altered in any tumor type or subtype analyzed. Thirdly, it is also possible to 
explore the importance of a particular module in many cancer types. A user is able to load 
their own modules (sets of genes) and ascertain if they are enriched for genes altered in any 
type of cancer.  
 
Supplementary Table 2. IntOGen.org main options. 
 
Option Description 
Gene Search Search for a gene of interest and have a wide view of the implication of 
this gene in cancer. 
Experiment search Search for a particular experiment and identify the most significant genes 
and modules altered. 
Tumor type search Search for a cancer type of interest and discover the most significant 
altered genes and modules given the combination of a number of 
experiments. Browse into the individual experiments used for the 
combination. 
Cancer Gene Prioritization Prioritize a list of candidate genes based on CGPrio probabilities and 
oncogenomic alterations. 
Combine experiments Choose a group of experiments and combine the statistics to obtain 
combined significant genes and modules. 
Analyze your modules Load your own modules and find out if they are enriched for genes 
significantly altered in different cancer types. 
 
 
Prioritization of candidate cancer genes is a key issue in cancer research. High-throughput 
approaches are able to identify large number of altered genes, at which stage it is necessary 
to prioritize the more interesting candidates for further study. IntOGen provides a means of 
prioritizing candidate cancer genes based on two principles: i) prioritization by similarity to 
known cancer genes using key gene properties (based on our published method CGPrio)22 
and ii) prioritization based on alterations found in different cancer types. The collection and 
statistical analysis of a large amount of published oncogenomic experiments provides a user 
with a measure of the relative importance of candidate cancer genes in different types of 
cancer. The combination of these two independent prioritization protocols can assist the user 
in making an educated decision on which genes to focus for further study.  
 
In summary, IntOGen.org is a unique and high valuable resource for the research community 
studying cancer that facilitates the interrogation of a substantial amount of data from genome-




The use of high-throughput techniques, such as microarrays and more recently sequencing 
techniques, has come to the fore in modern cancer research. In addition to the vast amount of 
oncogenomic data produced to date, projects such as the International Cancer Genome 
Consortium17 will generate a deluge of data over the coming years. However, integrative 
methodologies are necessary to take full advantage of these valuable data so as to unravel 
tumorigenic processes and identify the causative genes and pathways. 
 
Most publicly available cancer databases do not facilitate the analysis of different 
oncogenomic datatypes across numerous cancers. IntOGen is a novel framework that 
addresses this problem by collating, organizing, analyzing and integrating genome-wide 
experiments that study several types of alterations in different cancer types. IntOGen explores 
the data at different levels, from individual experiments to combinations of experiments that 
analyze the same tumor type, and from individual genes to modules (or gene sets).  
 
All IntOGen components are designed to be modular, updatable, flexible, extensible and 
efficient. We plan to update IntOGen regularly at different levels: i) including new 
experiments, ii) including new biological modules, iii) including new alteration types (such as 
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epigenomics and proteomics data when available) and iv) updating gene annotations as they 
are updated in Ensembl. Additionally, we plan to extend the system with new options and 
methods, such as analysis pipelines for data generated with new generation sequencing 
methodologies and visualization of data at the level of genome coordinates. 
 
Other resources have been developed previously with the objective of collecting and 
analyzing specific oncogenomic data. For example, Oncomine11, is a collection of expression 
profiles in cancer, Progenetix10, an  online repository for molecular cytogenetic aberration 
data and COSMIC23, which is a catalog of somatic mutations in cancer.  
 
IntOGen contains many features that are distinct from these and other recently developed 
integrative resources such as UCSC Cancer Genome Browser16, Rembrant15 or the 
Integrative Genomics Viewer24. For example, the integration of multiple alteration types under 
the same framework, the inclusion of numerous cancer types and subtypes, the structured 
clinical annotation of experiments (using ICD terms), the specifically designed statistical 
framework, the combination of results from independent experiments that analyse the same 
tumor type and the original and powerful visualization system are all elements that distinguish 
IntOGen. These tools permit the IntOGen user to identify those genes that are more 
significantly altered in a particular tumor type taking into account several independent 
experiments, giving a more comprehensive view of the implication of this gene in cancer. 
Also, analysis of novel combinations of experiments, selected by the user, can be performed 
through the web portal (www.intogen.org). 
 
In conclusion, IntOGen is a unique and high valuable resource for the cancer research 
community. We expect that it will be highly useful and will assist cancer researchers in their 
projects by allowing them to explore the significance and effects of genes and modules in 
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Supplementary Notes 2. Exploring Glioblastoma TCGA expression data with 
IntOGen 
 
1. Identification of Significantly Altered Genes 
 
We have used IntOGen methods to identify genes significantly altered at transcriptomic level 
in glioblastoma using The Cancer Genome Atlas experiment21. One important advantage of 
IntOGen is that individual experiments can be explored and analyzed in the context of other 
oncogenomic experiments available. This gives a necessary perspective to investigate if the 
alterations detected in a particular experiment are common to other tumor types, or specific to 
tumor type of interest. In Supplementary Figure 5, selected genes found to be significantly up-
regulated in TCGA expression data are compared to other experiments for brain tumors 
available in IntOGen and to combination of experiments from many other tumor types. We 
see that up-regulated genes in TCGA experiment agree especially with the results by Sun L. 





Supplementary Figure 5. Comparison of selected genes that are significantly up-regulated in TCGA 
expression data to other tissue types and other experiments studying brain from IntOGen. Each cell in 
the color matrix shows with a color scale the result of the analysis to assess how altered is a gene in a 
particular experiment or tumor type (combination of experiments for a particular tumor type). Colors 
toward red indicate that the gene is significantly altered in this experiment or tumor type. Gray means 
that it is not significantly altered. White cell denotes that this gene has not been analyzed for this 
experiment or tumor type. 
 
We can see that some genes like NUSAP1 or TGFBI are over-expressed in all or almost all of 
tumor types for which we have data. On the other hand, other genes like LTF or AQP1 seems 
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2. Analysis of Functional Modules 
 
Significantly altered genes might share interesting biological properties. The aim of the 
module analysis is to detect any such patterns in the data. IntOGen contains many useful 
modules to do these analyses.  
 
In the original TCGA publication, the authors point to the alteration of major pathways 
implicated in glioblastoma21 to be the target of unequivocal alterations (such as somatic 
nucleotide substitutions, homozygous deletions and focal amplifications)38. They perform a 
one-by-one mapping of altered genes to these 3 pathways: (receptor tyrosine kinase) RTK 
signaling, Rb pathway and p53 signaling pathways. A similar view of glioblastoma 
carcinogenesis is obtained from IntOGen module analysis of expression data. Supplementary 
Figure 5 give results of the enrichment of KEGG pathways and GO biological process in 
genes up- or down-regulated in TCGA glioblastoma expression data. In the case of GO 
biological process, some of the significant terms in up-regulation are “cell cycle”, “mitosis”, 
“DNA replication”, etc. (Supplementary Figure 6A). The enrichment analysis of KEGG 
pathways in up-regulated genes also gives a similar result. “Cell cycle” and “p53 signaling 
pathway” are the top 2 significant modules enriched in genes up-regulated in glioblastoma. In 
addition to these major pathways, we see that “phophoinositide-mediated signaling” is also 
de-regulated (Figure 6B). The authors of the original paper point to the importance of 
activating somatic mutations of PI(3)K complex in glioblastoma38. Concordance of the module 
analysis results for expression with the results reported in the TCGA paper shows that 
although transcriptomic changes are not direct causes of oncogenomic transformation, the 
cumulative result of implicative changes can be read from the alteration patterns in 
expression with the aid of module analysis. 
 
In the case of down-regulated genes, we see enrichment of nervous system related 
processes “axon guidance” and “nervous system development”, which indicates that a 
significant number of genes having these biological annotations are down-regulated in TCGA 
expression data (Supplementary Figure 5B). A similar situation is seen for KEGG pathways: 
“axon guidance”, “GnRH signaling pathway”, “neuroactive ligand-receptor interaction” 
pathways are enriched in down-regulated genes (Supplementary Figure 5B). This points to 
the de-differentiated state of the glioblastoma samples in the dataset. 
 
 
Supplementary Figure 6. Module analysis of KEGG pathways and Gene Ontology biological 
processes in TCGA glioblastoma expression data set. The colors indicate the significance of the 
enrichment analysis. Colors toward red indicate significant enrichment of the module in up or down-
regulated genes. Gray means no significant enrichment. 
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Oncogenomics data collection and pre-processing 
 
The current version of IntOGen includes oncogenomic data related to transcriptomic, copy 
number alterations (CNA) and somatic mutations obtained from different public data sources 
(Table 1). Transcriptomic and CNA datasets contain a number of samples each from a cancer 
patient. For these two types of alterations, due to statistical considerations, only those data 
sets containing at least 20 cancerous samples were included. For clinical annotations, we 
used International Classification of Disease for Oncology 3rd edition (ICD-O-3), for a number 
of reasons: 1) It is the international standards of World Health Organization for all general 
epidemiological, many health management purposes and clinical use. 2) Many widely used 
terminologies such as SNOMED and NCI Thesaurus have mappings to ICD. 3) It is the choice 
of standard for large-scale projects such as International Cancer Genome Consortium. 4) It 
has terms containing tags such as “Not Otherwise Specified” (NOS) and “Not Elsewhere 
Classified” (NEC) to indicate the clinical information is not specific enough to assign a term 
and is more specific than the coding system, respectively. Unfortunately, the former is the 
case for many of the data in public databases. Therefore, ICD is very helpful to avoid 
annotation mistakes. In the case of transcriptomic experiments, samples were manually 
annotated according to the descriptions provided by the authors. In the case of data obtained 
from Progenetix, all samples had already been manually annotated according to ICD. For the 
somatic mutation data a mapping was created manually from the clinical terms in Cosmic to 
ICD and the annotations therefore were done automatically. When there was not enough 
information to assign an ICD term, we kept the most general ICD term with the “NOS” tag. Still 
in some samples, no details about histology were indicated (for example only “breast 
cancer”). We did not assign any histology annotation to such samples but maintained 
topographical annotation only. 
 
Transcriptomic data include expression profiling experiments for mRNA for cancerous and 
non-cancerous samples on several different commercial/non-commercial platforms. All the 
data obtained from public databases were retrieved with R scripts using the Bioconductor 
packages ArrayExpress and GEOquery25. Those experiments satisfying IntOGen 
requirements were curated manually and classified according to the type of the platform used 
and the availability of raw data. Subsequently, preprocessing was done according to these 
criteria with R scripts in the following way: For two-channel experiments, raw data were 
background corrected and normalized using the variance stabilization method from “Limma” 
package26 of R Bioconductor25, while Affymetrix data were normalized using RMA 
normalization from the “affy” package27 from Bioconductor. In either way, the result is an 
absolute reading per probe for each sample in that experiment. Non-cancerous samples from 
the same experiments were pooled to obtain the “normal” expression value for each probe in 
that experiment taking an average of the absolute readings. Differential ratios were calculated 
for each cancerous sample dividing the absolute reading for each probe by the corresponding 
average normal value from the same experiment. In the cases where only processed absolute 
readings were available, assuming the data was already pre-processed, ratios were 
calculated directly from these absolute readings without normalization. Still in some cases 
only ratios were available, which were used as is. Probe-level log2 ratio data was fed into the 
analysis pipeline to detect driver alterations in that experiment. However we also store the 
pre-processed data at the level of probes so that when a newer version of Ensembl is 
released we can re-do the genomic annotation without the need to repeat this step.  
 
Large-scale genomic data are also highly heterogeneous including data from techniques such 
as spectral karyotyping (SKY) or array comparative genomic hybridization (arrayCGH), etc. 
From Progenetix database, data were obtained in the form of lists of genomic regions 
amplified or deleted in different cancer samples mapped to UCSC GoldenPath. The genes in 
these regions were mapped to Ensembl genes using the mapping provided by UCSC using 
Fjoin28. In the case of aSNP data from Sanger, the data was analyzed using the 
“aroma.affymetrix” package. The resulting amplified and deleted regions were mapped to 
Ensembl genes using Fjoin. 
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Identifying driver alterations (OncoDrive method). 
 
Copy Number Alterations 
We start at the level of a single experiment. For each gene in the CNA data a binary criterion 
was applied in order to extract the information about its amplification and deletion. For both 
cases, a value of 1 was assigned if a gene was amplified (deleted) and 0 otherwise. The 
resulting two binary matrices were used to calculate a separate alteration score for each 
event. We assume that the genes that are altered in more samples than expected by chance 





X1,...,Xm  binary random variables representing the 
€ 
m  genes present in the 
experiment, each having 
€ 
N1,...,Nm  observations (replicates). We employ binomial distribution 
to model the data, assuming that every gene 
€ 
i  was sampled from the 
population
€ 
Xi ~ Bin(Ni, p), where parameter 
€ 
p  denotes the probability of 
amplification/deletion (observing 1 in the array). The estimate of 
€ 
p  per experiment was 






samples present in the array. That is to say, if 
€ 









 [Eq. 1]. For a given experiment, the cumulative probability of observing an 
altered behavior of a gene 
€ 
i  at least 
€ 
ni times in a random sample of size 
€ 
Ni  is given by: 
€ 











∑ pk 1( − p)Ni −k  [Eq. 2] 
 
In order to maintain the unified framework of the analysis and increase the reliability of 
results, we selected only experiments with 20 or more samples. We believe that smaller 
numbers of replicates in a large-scale study can lead to anomalous conclusions. 
 
The p-values were subsequently corrected for the multiple testing using the adaptive false 
discovery rate procedure of Benjamini-Hochberg (BH-FDR)29. Suitable control for the 
presence of false positives is crucial, therefore, we also inspected the improvement obtained 
by using pFDR of Storey et al.30. We compared the two types of corrections through the lists 
of significantly altered genes determined at the corresponding significance levels of the 
corrected p-values and the q-values. The results were identical for all but a minor fraction of 
cases, where the estimates of 
€ 
p  were particularly small (<0.005). In principle, however, for 
our data m is of a magnitude of tens of thousands and typically there will always be some 
rejections (genes selected as non-altered). Therefore, to maintain the relative computational 
feasibility of the pipeline, we concluded that BH-FDR provided a sufficient control for the 
power of the test whilst keeping the Type I error at the pre-specified level.  
 
Transcriptomic Alterations 
For the identification of driver transcriptomic alterations, the analysis was done at the level of 
probes. In order to represent the transcriptomic data in a fixed-scale manner, it was 
discretized with respect to up-regulation and down-regulation separately. It is crucial to note 
that the same probe can be altered in either direction: both up and down regulated. In order to 
capture this behaviour, the information from each replicate must be included.  Our goal is to 
measure the changes in expression of a probe at the level of each sample, which in essence 
is different to modelling it with respect to the overall probe variation in expression or its pooled 
correspondent across the entire experiment.  
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We designed a dynamic fold change criterion to investigate the altering behaviour of cancer 
genes. The restriction to the general use of fold change and its main source of criticism lies in 
the heuristic choice of a cut-off (typically ranging from 1.5 to 3). Commonly, an arbitrary cut-
off is set prior to the analysis based on the expectations or other heuristic assessment. 
However, a global cut-off applied to different experiments requires that the genes within them 
exhibit a roughly identical distribution of ratio values for the chosen value to fall in the 
relatively similar point in the distribution of expression levels. The fact that we separately 
analyze up- and down-regulation mitigates the effect of a random gene pertaining to a 
selected gene list due to small variation or other probe specific effects. 
 
The assignment of the fold change cut-off for an experiment 
€ 
i , denoted as 
€ 
Ki, was motivated 
by its binary representation and the principle of binomial modeling. The approach has a clear 
geometric interpretation. Let us recall that 
€ 
p  represents the frequency of alterations in an 
array. By sliding the value for the fold-change cut-off, one implicitly influences the estimated 
value of 
€ 
p , see equation [1]. That is to say, low values of 
€ 
Ki incur the inclusion of high 
number of false positives, which subsequently drops with the increase of the cut-off and a 
decrease of 
€ 
p . The crucial step is to determine when the optimal threshold is attained.  In 
other words, since the number of samples is fixed and given for every probe, the 
reproducibility of the relevant order of the computed significance levels is maintained when 




Δp , are not affected by the shifts in 
€ 
Ki. However, it is not 
sufficient to impose 
€ 
Δp < ε, as it is hard-wired to the number of replicates in the experiment 
€ 
i . 
Such a universal unit of measure, however, can be set through inspecting the decrease of the 
slope of the tangent of the line fitted to the points determined by the estimates of 
€ 
p  against 




We computed the fold changes in the range of [0,…,7] at the intervals of 
€ 
h = 0.1. The steps 
€ 
h  should be chosen optimally to capture the underlying changes. The results for a selection 
of experiments are depicted in Supplementary Figure 3. Denoting by 
€ 
a  the slope of the 
tangent line 
€ 
Ki was selected (drawing the vertical line) at the point when 
€ 
{maxa : a ≤ 0.05}  
was first attained. As the slope converges to 0 the number of probes altered in an experiment 
remains stable. When 
€ 
Ki bypasses the maximum ratio change in the array, no probes will be 
selected. Also, the steps 
€ 
h  should be chosen optimally to capture the underlying changes. 
The advantage of determining the cut-off point for each experiment is that we do not make 
any assumptions about the percentage of altered genes, e.g. experiments with a few altered 
probes and experiments with considerable percentage of altered genes have been recorded, 
consistent with known variability in mutational phenotypes of different cancer samples. The 
former would be visible as a fitted slope with large decrements of 
€ 
p  and no clear 
convergence point, the latter would have a steep drop for smaller values of 
€ 
Ki and a long tail. 
 
The data discretized by the fold-change transformation step takes the binary form as in the 
case of the CNA data and the analysis proceeds analogously. After the detection of 
significantly up- and down-regulated probes, the probes are mapped to Ensembl genes using 
the mapping obtained from Ensembl Mart database. When more than one probes were 
mapped to the same genes, we maintained the most significant value. After this stage, we 
combine the p-values for the same gene from different experiments (see the next section). 
 
Combination of independent experiments 
 
We further investigated the extent to which the combined evidence among studies supports a 
particular biological hypothesis. Therefore, having computed the significance for alteration 
events within individual studies, we are interested in the pooled information coming from 
different experiments analyzing the same cancer type/subtype. Annotation of the experiments 
using the ICD terms is crucial for the combination and merging evidence from multiple studies 
and provides an insight into the patterns shared among the experiments with the same 
annotation. 
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However the heterogeneous nature of the data makes it difficult to compare different datasets. 
For example, we included microarray data using different platforms or even different 
methodologies (single-channel vs. dual-channel). Therefore, the individual experiments are 
often not directly compatible for producing a single combined data set on which to conduct a 
second meta-analysis. Fortunately, one can still produce a combined test of significance of 
alteration events across a set of experiments with the same clinical annotation19.  
 
Prior to pooling evidence from distinct experiments, p-values for the same alteration from 
experiments with the same annotation, were corrected across all studies by means of BH-
FDR procedure as before29. We employed the generalized weighted Z-method20, to combine 
evidence from independent studies. This pooling method was proved to perform well on 
sparse data and small values of significance level (previous applications to cancer studies 
can be found e.g. in 31). The gene sets we analyzed were already pre-screened for having 20 
or more replicates at the level of a single experiment, thus we can assume the validity of the 
normal approximation to the binomial distribution.  Consequently, the restriction on the data 
size is not model driven, but simply a trade-off between maintaining high accuracy of the 
results and data reduction.  The formula of Liptak-Stouffer for pooling evidence from the 
collection of studies, 
€ 
ne , uses the inverse-transformation of the standard normal distribution 

















Zi,g  is the z-score from the i-th experiment and 
€ 
ω i  is the weight assigned to the 
experiment. Weights were chosen to be a function of the respective sample sizes. Namely, 
they represent the relative fraction of samples of a gene 
€ 
g  in the experiment 
€ 
i  to the number 
of its replicates in all experiments. Thus, the computed z-score is easily interpreted: values 
close to 0 indicate no significant alterations (e.g. in a given cancer type), while the significant 
changes will lie in the right tail of the standard normal distribution. 
 
By default we compare all the experiments with the same ICD annotation. We also provide an 
option in which the user is free to choose the experiments he/she thinks are more reliable or 
interesting to combine and see the overall significance of alterations when the results are 
pooled from their studies of choice. 
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Supplementary Figure 3. Plots used to determine the cut-off of Log2 Ratio for three different 
experiment units (up-regulation and down-regulation for TCGA glioblastomaexpression data and up-
regulation for Richardson et al., 2007). The plots in the left show the dynamics of p (frequency of 
alterations in an array) over different Log2 Ratio cut-offs (red line) and the assigned cut-off (blue line) 
coinciding with the point where the slope of the tangent line reaches 0.05. The plots in the right show the 
dynamics of the slope of the tangent line over different Log2 Ratio cut-offs (red line) and the point where 
the slope reaches 0.05 (blue line). 
 
Identifying driver modules. 
 
When we identify the significance of alterations at the level of genes, genes are assumed to 
be independent from each other. However, genes related to each other in some biological 
way might share similar alteration patterns. To be able to detect such tendencies in the 
oncogenomic data, we analyze the p-values of genes by enrichment analysis of different 
modules. Namely, a module constitutes a set of genes having a similar biological property: 
genes with the same GO biological process, molecular function annotations or genes 
predicted to be bound by the same transcription factor. 
 
The statistical analysis was performed based on the suitably adjusted information computed 
at the previous stages of the analysis. The procedure is the same for both CNA and 
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transcriptomic alterations. Again, we use the binomial distribution to determine functional 
enrichment of a list of genes within a module. As opposed to its alternatives (hypergeometric, 
Fisher) it sidesteps the necessity for an explicit assumption of the size of the population. 
Taking as input the lists of the binomial p-values for each gene under consideration, the BH-
FDR correction was applied across the pooled list (merged list of p-values for all the genes in 
all modules). In this way, we are taking into consideration that though the same null 
hypothesis was tested, the data came from heterogeneous sources. In order to detect 
significantly altered modules, the corrected p-values were again classified into significant vs 
non-significant classes according to the binary criterion with the threshold of 
€ 
α=0.05: 1 was 
assigned to the significant p-values, 0 otherwise. This transformation allows use of the 
procedure introduced before (see equations 2 and 3).  It needs to be noted, that in this setting 
Z-score reflects the information within the module, as opposed to a gene within experiments 














 [Eq. 4] 
 
The BG-FDR corrected p-values 
€ 
≤α  indicate significant enrichment of a selected module in 
a selection of experiments. 
 
 
Biological modules collection. 
 
Functional Modules: Gene Ontology32 annotations for Ensembl genes were downloaded from 
Ensembl v5133. Pathway annotations for Entrez gene ids were directly taken from KEGG34 
and mapped to Ensembl genes. 
 
Regulatory Modules: For transcription factors binding sites prediction, we scanned -600 to 
+100 from transcription start site of Ensembl v51 transcripts with position weight matrices 
from TRANSFAC35 v2009.1 version using the program STORM36. Those predictions with p-
value <1.4x10E-5 were assumed to be significant as suggested by the authors of the 
program. miRNA prediction were downloaded directly from mirBase v537. 
 
OncoModules: OncoModules at the level of combination (genes altered when the results for 
experiments having the same ICD annotations were combined) were obtained applying a cut-
off of 0.05 to the combined p-value. OncoModules for each experiment are obtained in the 
same way, however this time the corrected p-value for the corresponding experiment is used. 
 
General Schema of The Project Organization 
 
In terms of architecture, IntOGen system can be divided into four main components (Figure 
4): the persistence layer responsible for data storage, the command line tools, the analysis 
workflows and the web application. Each component has well defined responsabilities and 
interfaces which allows interaction between them and extensibility of the system with new 
components when needed. We have developed a modular system applying software 
engineering methodologies (object oriented programming, agile development) and 
technologies (such as Maven for project management and Subversion for control version). 
 
The persistence layer consists of a distributed file system and a MySQL database, a 
relational database management system (RDBMS). In the file system we store raw and 
processed data together with annotations (as xml formatted and tab-delimited files). We 
designed a special xml format for storage of the oncogenomic data annotations according to 
the data model. This format is intuitive enough to allow system users and curators to 
annotate data manually, if necessary, in an easy way. Once the data is in the proper xml 
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format, it can be imported to or updated in the relational database as well as exported back 
again in order to do backups or to transport to other databases. The data model is defined in 
a high level language (Java) using Hibernate framework. Hibernate is responsible for 
generation of the SQL schema, management of connections, transactions (when executed in 
an enterprise container), caching and so on. It provides many advantages at a low 
performance cost when properly configured. To expand the data model we only need to 
define new java classes. We maintain an independent database for each release for results 
generated in our laboratory, and in addition to those we can create user specific databases 
for the results calculated for custom combinations allowing to scale well with the number of 
growing users.  
 
Additionally, we have developed command line tools that allow easy management of the 
data, such as import-export tasks and do queries in a high level language called HQL 
(Hibernate Query Language). New tools can be added easily as needed. 
 
The analysis workflows (also known as pipelines) are implemented with Makefiles in order to 
facilitate management of task dependencies and cluster submission for parallelization (using 
Sun Grid Engine). Makefiles can be used to call the methods applied in IntOGen or any other 
tool that can be used through the command line (independently of the language they are 
programmed in). By generating workflows with Makefiles and queries to access the data 
from the database (or even, if necessary, from the file system), we can incorporate new 
methods to the system easily. As the analysis is run in a cluster of computers we can add 
more nodes to scale for more data and computational requirements. 
 
The final component, the web application, is the main interface for the end-user of the 
system and allows browsing the data, results, annotations, etc. (see next section for details). 
It is implemented using one of the latest Java web technologies (Apache Wicket) that 
simplifies web development and therefore the addition of new features to the system easily 
without loss of power nor capabilities. 
 
Each component is deployed in the best-suited hardware infra-structure with future load 
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Supplementary Figure 4. Technical Architecture of IntOGen. IntOGen system can be divided to four 
main components: the persistence layer responsible for data storage and permits interaction with the 





Integration of information coming from different experiments requires the use of a common 
annotation system. This annotation problem poses two challenges to any similar integrative 
effort: a) the design and implementation of a generic and flexible data model and b) adoption 
of structured vocabularies. a) We have devised a data model for the annotation generic 
enough to incorporate any relevant information related to samples, platforms, experiments, 
etc. which could be based on a formal vocabulary or free-text (see Fig. 5). Similarly, the 
analysis pipeline is designed so that it does not rely on the type of annotations used. 
Therefore one could easily convert the annotations to another vocabulary automatically 
provided that there is a mapping between the two vocabularies and run the same pipeline. 
Similarly, one could use other relevant information about the samples such as tumor stage to 
group them and perform similar analysis.  
 
 
Figure 5. Schema of the annotation system 
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This chapter is about the Biomart interface of IntOGen. The program-
ming part of this work was performed by Christian Perez. I helped him
in the concept and wrote the manuscript. The following paper is under
revision.
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Recently we created IntOGen(1), a resource to integrate large amount of cancer genomic data. 
IntOGen aims at facilitating the detection of the most recurrent alterations that drive 
tumorigenesis. It collates, annotates and analyzes high-throughput data about transcriptional, 
genomic and mutational changes taking place in tumors from different studies annotated with 
specific cancer types. Currently it contains 73 studies for mRNA expression profiling and 726 
studies for genomic alterations covering in total 75 different cancer types. In this paper, we 
describe the Biomart(2) portal for IntOGen. The portal provides easy access to different types of 
data and facilitates the bulk download of the all analysis results. Here we describe the general 
features of IntOGen and give example queries to demonstrate its use. 
Database URL: www.intogen.org. 
 
Project Description 
Tumorigenesis is characterized by the accumulation of a multitude of alterations. With the recent 
explosion of high-throughput cancer data, it has been clear that the challenge is in sorting out the 
alterations that drive tumorigenesis from those that are only byproducts of the highly proliferative 
life styles of tumor cells. Moreover, the existence of different alteration types makes the detection 
of causative ones even more difficult. Hence the need for integrative approaches is more 
pronounced. IntOGen was created to approach this need. IntOGen contains more than 800 
oncogenomics studies called “experiments”. An experiment typically comprises the high-
throughput analysis of a specific type of alteration (or alterations) in at least 20 tumor samples of 
a particular cancer type. Samples in all the studies are annotated with the same vocabulary, 
namely International Classification of Disease for Oncology (ICD-O)(3), which facilitate the 
automatic integration of multiple experiments studying the same tumour type (ie. annotated with 
the same ICD term). For each tumor we include in IntOGen we annotate the topography and 
morphology using ICD terms. 
 
In IntOGen framework, the analysis is performed at different levels: On one side each experiment 
is analyzed independently (experiment level) and those experiments studying the same tumor type 
are combined (combination level). Also on the other side the analysis is performed at the level of 
genes (gene level) and at the level of modules (module level). A module is defined by a set of 
genes with some biological property in common, we currently analyze Gene Ontology modules, 
KEGG pathway modules, modules derived from genes sharing a transcription factor binding side 
(TFBS) in their promoter and genes sharing microRNA target motifs in their 3’UTR.  
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First, within each experiment, we detect the most recurrent alterations among the samples with 
the assumption that genes that are altered in more samples than expected by chance are somehow 
important for the development of the tumor. The results for the same gene can be combined 
statistically across the studies that analyze the same cancer type (same ICD term). An advantage 
of ICD is its hierarchical structure. If the study contains enough samples (at least 20) for which 
the morphology type information is known, then detection of significant alterations can be done 
at both the level of cancer type (topography) and the level of subtype (morphology). In this way 
alterations specific to subtypes can be identified as well as those common to that type of cancer in 
general.  
 
After significantly altered genes are detected, another integration is done to find the relationships 
between the altered genes with respect to the modules (e.g. biological processes or pathways) 
they belong to. Different genes from the same pathway might be altered in different tumors 
resulting in the same net effect on the same pathway (gene/module). Hence, enrichment analysis 
with functionally and biologically related gene sets helps detect more broad-spectrum patterns in 
the data. 
 
As can be expected, the interpretation of these highly inter-related results requires powerful 
visualization methods. The browser of IntOGen facilitates the exploration and intuitive 
visualization of results at different levels (available at: http://www.intogen.org), while the 
Biomart portal (available at: http://biomart.intogen.org) allows complex queries and facilitates the 
bulk download of the all analysis results.   
 
Data Content 
The data in IntOGen consists of publicly available experiments collected from databases such as 
Gene Expression Omnibus (GEO), ArrayExpress(4), Cosmic(5), Progenetix(6) and cancer data 
portals for projects such as The Cancer Genome Atlas(7). From the Biomart portal, 
transcriptomic alteration (up-regulation or down-regulation) and copy number aberration (gain or 
loss) results at different levels can be accessed. The data provided from Biomart portal is of three 
types: experiment-level matrices, combination-level matrices and oncomodules. Within each 
type, the user can access data either at the level of genes or gene modules for different cancer 
types/subtypes or experiments. Gene-level matrices contain a value per gene reflecting 
significance of alteration. They can be used as data files for further down-stream analysis. 
Oncomodules are sets of genes significantly altered in a specific experiment or combination. A 
summary of the data currently available in IntOGen is provided in Table 1. Table 2 list and 
describes all the datasets available. 
 
available available 
21 cancer types 75 cancer types 
53 cancer subtypes 353 cancer subtypes 







Table 1. Summary of IntOGen data available through the BioMart interface. 
 
Query Examples 
In IntOGen Biomart portal, users can query for three types of data. For each type there is a 
database; IntOGen Experiments, IntOGen Combinations and IntOGen Oncomodules. 
 
In IntOGen Experiments database, there are datasets for genomic and transcriptomic alterations. 
Users can query the results of the recurrence analysis for these alterations at the level of genes or 
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modules such as KEGG pathways and Gene Ontology (GO) categories for each experiment 
included in IntOGen. For both types of datasets, the results can be filtered in many different 
ways. Here are a few examples: genes annotated with a list of GO ids, genes in a specific 
chromosomal band, a list of selected favorite Entrez/Ensembl gene ids. The user can also filter by 
significance level and the results can be restricted to experiments done by specific authors, 
performed on a specific platform type, etc. The columns in the results can be determined by the 
selections done in attributes section. For experiment-level data, there are a number of statistics 
that can be retrieved such as the number of samples in the experiment, the expected/observed 
number of alterations and p-values etc. What is retrieved is a table that contains the selected 
attributes for the genes or modules. In this way, data matrices can be constructed for further 
analysis.  
 
In IntOGen Combinations database, users can query the results for combinations, that is the 
integration of results from experiments annotated with the same cancer type. This database 
includes datasets for genomic and transcriptomic alterations for genes and modules. The filters 
and attributes works in a similar way as in Experiment database however only p-value of 
alteration is available as a statistic.  
 
In IntOGen Oncomodules database, there are two datasets, one for combinations and one for 
experiments. Each dataset contains lists of genes that are significantly altered in a specific 
combination of ICD terms or in a specific experiment. Again the user can filter the results in a 
variety of ways, with the significant level he/she likes, according to certain characteristics of 
genes, for a cancer type and, in the case oncomodules at the level of experiments, for author or 
platform type. Following are example queries to access the data in IntOGen. 
 
 
Query #1: Use a list of genes to check whether they have been significantly gained or lost in the 
topology breast. 
  






Genes: ID List limit by a file 
with ids (Ensembl, Entrez 
etc.) Ensemble ID  
 
 
ICD-O: breast; ANY 
morphology 
References: 
Entrez Gene id 
    Gene symbol 
     Gain p-value 
     Loss p-value 
The result of high-throughput analysis is usually a list of genes such as genes significantly 
deregulated in expression or lost in a genomic region. As resources are limited, for downstream 
analysis, this gene list must be prioritized. One way to do this is to check if the individual genes 
are altered in any way in the panel of cancer experiments in IntOGen. In Query 1, the user can 
download the combined results for genomic alterations filtering them with their gene list. 
 
 
Query #2-3: Find the genes gained in lung cancer. Check the transcriptomic alteration status of 
the genes gained in lung cancer. 
  
Query 2: 
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ICD-O Topography & 
Morphology: lung; ANY 
morphology  
    
 
Query 3: 





Genes: ID List form the 
previous query Ensemble ID 
   
ICD-O: lung; ANY 
morphology Gene symbol 
     
Up-regulation 
p-value 




There are different types of alterations taking place in cancer. It is important to cross-check the 
relative contributions of different alteration types. With Queries 2-3, one can compare the genes 
gained and transcriptionally deregulated in lung cancer. 
 
 
Query #4: Compare the genomic alterations in brain cancer in general and two specific subtypes;  
ependymoma and astrocytoma. 
 





ICD-O: brain, nos; ANY 
morphology Ensemble ID 
   
ICD-O: brain, nos; 
astrocytoma, nos Gene symbol 
   
 ICD-O: brain, nos; 
epedymoma, nos Gain p-value 
    Loss p-value 
Since the dissection of brain cancer into intrinsic subtypes has prognostic value, it has been the 
interest of experimental scientist to find gene list that can distinguish cancer subtypes. With 
Query 4, the user can download the genomic alterations in brain cancer and those for specific 
subtypes, epedymoma and astrocytoma. 
 
Query #5: Compare the expression level of the genes annotated with GO cell cycle term in 
different breast cancer experiments. Take the results from the experiment with the greatest 
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Filters: ID List limit by GO 
id GO:0007049 Gene symbol 
     
Upregulation p-
value 
    
Downregulation 
p-value 




    
While enrichment with modules is informative, the user can also get the results for the genes in a 
module. By comparing the two results, it is possible to see which genes from the pathway are 
more likely to determine the activity of the pathway in different experiments of the same cancer 
type. 
 














    KEGG name 
     
Upregulation p-
value 
    
Downregulation  
p-value 
While cancers from different patients show extensive heterogeneity in terms of the specific genes 
altered, the set of biological processes/pathway affected by these alterations are similar. 
Enrichment analysis of sets of genes with a specific biological property is very useful to detect 
such patterns. With Query 6, the user can retrieve the results for the pathways from KEGG for 
different experiments that study breast cancer. In addition, the user can also compare the 
pathways altered in independent breast cancer data sets. 
 
Discussion and Future directions 
IntOGen is a cancer analysis tool designed to facilitate the integration, analysis, exploration and 
interpretation of oncogenomic data. In addition to its browser, its BioMart interface provides 
access to high-throughput data related to genomic and transcriptomic alterations taking place in 
different types of cancers. A unique feature of IntOGen is that it provides analysis at different 
levels of integration. The user can compare the results for individual experiments to those 
obtained by merging the experiments studying the same cancer type. Both types of data are 
accessible through the BioMart interface. A major feature of the BioMart interface is that it 
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facilitates bulk download of the data. We will continue adding new data from public databases as 
well as cancer projects such as TCGA(7) and ICGC(8).  
 
Another advantage of using IntOGen is that the data downloaded can directly be analyzed in 
Gitools(9) (http://www.gitools.org), which is a stand-alone tool designed for the analysis and 
visualization of high-throughput data. Gitools can also be used to access all other available 
BioMart portals and import data ready to be visualized and analyzed with Gitools. For example, 
one can easily perform enrichment analyses on IntOGen data with modules or genesets from 
various Biomart portals to explore large-scale patterns in cancer genomics data (see 
http://help.gitools.org/xwiki/bin/view/Tutorials/ for examples). 
 
With cheaper and faster sequencing technologies being available continuously, a deluge of cancer 
genomics data is expected in the coming years. Resources like IntOGen that allow the integration, 
visualization and interpretation of large amount of oncogenomics data will gain importance. We 
continuously work on improvements and updates on the system to be able to incorporate the data 
obtained using sequencing technologies. With more high-quality data and new analysis methods 
incorporated into IntOGen, we expect it to become a useful resource for experimental researchers. 
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Table 2. Description of IntOGen datasets available through the BioMart interface. 
 
Databases	   Datasets	   Description	  
Gene genomic alterations Recurrence	   and	   significance	   of	   genomic	   alteration	   (gain	   and	   loss)	   for	   each	  
gene	  at	  the	  level	  of	  experiments	  
Gene transcriptomic alterations Recurrence	  and	  significance	  of	  transcriptomic	  alterations	  (upregulation	  and	  
downregulation)	  for	  each	  gene	  at	  the	  level	  of	  experiments	  	  
KEGG	  genomic	  alterations	   Recurrence	  and	  significance	  of	  genomic	  alterations	  (gain	  and	   loss)	   for	  each	  
KEGG	  pathway	  at	  the	  level	  of	  experiments	  
KEGG	  transcriptomic	  alterations	   Recurrence	  and	  significance	  of	  transcriptomic	  alterations	  (upregulation	  and	  
downregulation)	  for	  each	  KEGG	  pathway	  at	  the	  level	  of	  experiments	  
GO	  genomic	  alterations	   Recurrence	  and	  significance	  of	  genomic	  alterations	  (gain	  and	   loss)	   for	  each	  
GO	  term	  at	  the	  level	  of	  experiments	  
GO	  transcriptomic	  alterations	   Recurrence	  and	  significance	  of	  transcriptomic	  alterations	  (upregulation	  and	  
downregulation)	  for	  each	  GO	  term	  at	  the	  level	  of	  experiments	  
TFBS	  genomic	  alterations	   Recurrence	   and	   significance	   of	   genomic	   alterations	   (gain	   and	   loss)	   for	  
putative	  targets	  of	  each	  TF	  at	  the	  level	  of	  experiments	  
TFBS	  transcriptomic	  alterations	   Recurrence	  and	  significance	  of	  transcriptomic	  alterations	  (upregulation	  and	  
downregulation)	  for	  putative	  targets	  of	  each	  TF	  at	  the	  level	  of	  experiments	  
miRNA	  genomic	  alterations	   Recurrence	   and	   significance	   of	   genomic	   alterations	   (gain	   and	   loss)	   for	  
putative	  targets	  of	  	  each	  miRNA	  at	  the	  level	  of	  experiments	  
Experiments	  
miRNA	  transcriptomic	  alterations	   Recurrence	  and	  significance	  of	  transcriptomic	  alterations	  (upregulation	  and	  
downregulation)	   for	   putative	   targets	   of	   each	   miRNA	   at	   the	   level	   of	  
experiments	  
Gene genomic alterations Recurrence	  and	  significance	  of	  genomic	  alterations	  (gain	  and	   loss)	   for	  each	  
gene	  at	  the	  level	  of	  combinations	  (tumor	  types	  and	  subtypes)	  
Gene transcriptomic alterations Recurrence	  and	  significance	  of	  transcriptomic	  alterations	  (upregulation	  and	  
downregulation)	  for	  each	  gene	  at	  the	  level	  of	  combinations	  (tumor	  types	  and	  
subtypes)	  
KEGG	  genomic	  alterations	   Recurrence	  and	  significance	  of	  genomic	  alterations	  (gain	  and	   loss)	   for	  each	  
KEGG	  pathway	  at	  the	  level	  of	  combinations	  (tumor	  types	  and	  subtypes)	  
Combinations	  
KEGG	  transcriptomic	  alterations	   Recurrence	  and	  significance	  of	  transcriptomic	  alterations	  (upregulation	  and	  
downregulation)	  for	  each	  KEGG	  pathway	  at	  the	  level	  of	  combinations	  (tumor	  
types	  and	  subtypes)	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GO	  genomic	  alterations	   Recurrence	  and	  significance	  of	  genomic	  alterations	  (gain	  and	   loss)	   for	  each	  
GO	  term	  at	  the	  level	  of	  combinations	  (tumor	  types	  and	  subtypes)	  
GO	  transcriptomic	  alterations	   Recurrence	  and	  significance	  of	  transcriptomic	  alterations	  (upregulation	  and	  
downregulation)	  for	  each	  GO	  term	  at	  the	  level	  of	  combinations	  (tumor	  types	  
and	  subtypes)	  
TFBS	  genomic	  alterations	   Recurrence	   and	   significance	   of	   genomic	   alterations	   (gain	   and	   loss)	   for	  
putative	   targets	   of	   each	   TF	   at	   the	   level	   of	   combinations	   (tumor	   types	   and	  
subtypes)	  
TFBS	  transcriptomic	  alterations	   Recurrence	  and	  significance	  of	  transcriptomic	  alterations	  (upregulation	  and	  
downregulation)	  for	  putative	  targets	  of	  each	  TF	  at	  the	  level	  of	  combinations	  
(tumor	  types	  and	  subtypes)	  
miRNA	  genomic	  alterations	   Recurrence	   and	   significance	   of	   genomic	   alterations	   (gain	   and	   loss)	   for	  
putative	  targets	  of	  each	  miRNA	  at	  the	  level	  of	  combinations	  (tumor	  types	  and	  
subtypes)	  
	  
miRNA	  transcriptomic	  alterations	   Recurrence	  and	  significance	  of	  transcriptomic	  alterations	  (upregulation	  and	  
downregulation)	   for	   putative	   targets	   of	   each	   miRNA	   at	   the	   level	   of	  
combinations	  (tumor	  types	  and	  subtypes)	  
Combinations Sets	  of	  genes	  significantly	  altered	  in	  each	  cancer	  type	  and	  subtype	  Oncomodules	  
Experiments Sets	  of	  genes	  significantly	  altered	  in	  each	  experiment	  
	  
	  






Identification and characterization of subtypes of different cancers is of
great clinical interest. However, this question is not addressed in In-
tOGen. In the last chapter of the results part, I propose an enrichment
analysis-based methodology in order to detect distinct patient subgroups
from transcriptional profiling data. At the center of this method is enrich-
ment analysis at the level of the tumor samples in the data set. Hence,
instead of differentiating the samples in terms of genes, this method es-
tablishes the sample subgroups as a set of differentially enriched gene
modules. Comparing enrichment patterns of modules with clinical infor-
mation of the samples, one can determine if any module is related to any
clinical annotation such as survival. This type of analysis also provides
mechanistic explanations for why the sample groups are different. We
apply this methodology to data sets from multiple cancer types in order
to detect worse prognosis patients and later on dissect the transcriptional
patterns to identify their main characteristics. In this part, I conducted
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submitted.
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Shared properties of worse prognosis tumors in 
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Abstract 
Background Enrichment methods are widely used to analyze high-throughput functional 
genomics data. Here we used a methodology that integrates sample-level enrichment analysis 
results with expression levels of individual genes and clinical information in order to identify 
patient subgroups with different survival properties. We used it to test the statistical power of a 
senescence-related gene signature to predict subsequent tumor events and outcome in multiple 
cancer types.  
 
Methods   We collected publicly available microarray expression data sets that profile a large 
number of tumor samples from different cancer types. We also generated a library of functional 
modules and modules that consist of genes activated or deactivated in cells under different stress 
conditions such as deregulation of Rb pathway, DNA damage response and metabolic stress, etc. 
We performed functional enrichment analysis at the level of samples to see if gene modules are 
transcriptionally deregulated in specific tumors. Finally we compared the survival of the patients 
corresponding to the samples with positive enrichment to all the tumor samples in that data set. 
 
Results   We saw that, each patient cohort can be separated into those tumor samples with up-
regulation of Rb-E2F and another group with down-regulation. The patients for the former 
samples have significantly less survival than others in multiple cancer types. These samples also 
exhibit significant up-regulation of DNA damage pathways and mTOR signaling indicating that 
they become highly dependent on these pathways. 
 
Conclusions Using sample-level enrichment analysis, one can describe the difference between 
patient subgroups in terms of gene modules, hence pathways/processes they are related to. 
Moreover coupling it with survival analysis, prognostic gene signatures can be built. We use this 
methodology to show that a gene signature related to evasion of senescence-induced stress can 
be used to predict subsequent tumor events in multiple cancer types. Moreover, these tumors 
differ in their stress phenotypes; which gives indications about the therapeutic management of 





The usual way to perform enrichment analysis (EA) in a microarray data set (or any high-
throughput functional genomic screening for that matter) is as follows: First the genes that are 
differentially expressed between the samples with different properties are detected and then these 
transcriptional gene sets are studied for enrichment with sets of genes having a certain biological 
property such as Gene Ontology (GO) categories. However, even if understanding the genes that 
difer in expression between two groups of patients is of use, a module-level analysis provides a 
summary of the biological pathways/processes that define the two subgroups. Here we propose a 
different approach. Instead of detecting differentially expressed genes among samples, we detect 
differentially enriched gene modules by performing enrichment analysis at the level of individual 
samples (Figure 1). The enrichment pattern of samples is then compared to the available clinical 
properties. If the modules related to the pathway of interest are used, one can determine its 
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relative importance, if it exists, in different patient groups (Figure 1). We use this approach to 
test the following hypothesis.  
 
It has been proposed that, during the progression of cancer, the capacity of cancer cells to survive 
in the hypoxic and nutrient-deprived tumor microenvironment is a crucial step towards 
malignancy[1]. Adaptation to survival under these stress signals can override normal cellular 
stress responses, leading to the persistence and progression of the carcinogenic phenotype. 
Different sources of stress such as senescence-induced stress, metabolic, and oxidative insults 
represent a common set of oncogenesis-associated cellular stresses that cancer cells must tolerate 
through stress support pathways[2]. For example, to overcome the senescence barrier, malignant 
cells have been proposed to deregulate proteins in pathways mediating senescence such as Rb 
pathway. These alterations are collectively referred to as the stress phenotypes of cancers[2]. 
Hence, if indeed stress responses are important determinants of cancer progression, we asked if 
one could use stress phenotypes in tumor samples to explain their difference in survival. To this 
end, we use publicly available gene expression profiles of large cohorts of different types of 
cancers and gene signatures related to senescence-induced and metabolic stress phenotypes. We 
performed EA in each tumor sample in each patient cohort in order to detect differentially 
enriched modules. We show that the extent to which cancer cells transcriptionally abrogate 
senescence-inducing Rb signaling is an indicator of bad prognosis. These tumor samples exhibit 
dependences in certain stress support pathways. Moreover, we demonstrate the prognostic power 
of the senescence-related gene signature in pancreas, bladder and brain cancers and showed that 





We collected publicly available expression profiling data from Gene Expression Omnibus (GEO) 
(Table 1). Each data set consists of microarray expression data for a large number of patients. 
Raw data was downloaded for all datasets. In the case of Affymetrix data, CEL files were 
processed and normalized using the rma function in the “affy” package of R Bioconductor[3]. 
Non-Affymetrix one-channel data was normalized using vsn normalization method in Limma 
package of R Bioconductor[4]. For two-channel data (GSE22133 only), after background 
subtraction, vsn normalization was performed. In all cases, the result of normalization is log2-
transformed absolute reading. Each gene in the normalized expression matrix was median-
centered across all the samples in the matrix and divided by the standard deviation.  
Gene Modules 
Gene modules were collected from Gene Ontology[5], KEGG pathway database[6], MSigDB[7] 
and the supplementary data sets of the indicated publication (Table 2). 
Functional Enrichment 
Sample-level functional enrichment analysis was done using Gitools[8] (http://www.gitools.org). 
Gitools offers a number of statistical tests to assess the enrichment of gene modules in high-
throughput data such as expression profiling. We used zscore-median method, which compares 
the median expression value of genes in each module to a distribution of random modules of the 
same size drawn from the expression values for the sample. The result is a z-score, which is a 
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measure of the difference between the observed median expression value compared to the 
expected. Positive and negative z-scores indicate a significant number of genes in the module are 
up-regulated and down-regulated in the condition, respectively. 
Survival Analysis 
Cox proportional hazard test from “survival” package of Comprehensive R Network was 
used[9]. 
 
Results and Discussion 
Oncogene-Induced Stress 
It has been proposed that intrinsic growth-suppressive mechanisms are hardwired within the 
networks that drive cell proliferation[10]. One such mechanism is oncogene-induced stress that 
induces senescence[11-13]. The deregulation of mediators of this senescence response, such as 
Rb or p53 pathways, is an important survival strategy for cancer cells. Rb exerts its anti-
proliferative influences through its inhibitory effect on E2F transcription factors[14]. Prompted 
by this observation, we set out to establish a gene signature that could be used to predict the 
status of Rb pathway through sample level EA in transcriptional expression data of tumor 
samples. We performed EA in expression profiles of primary breast tumor samples with a set of 
genes that are repressed by Rb-E2F when Rb signaling is functional (referred to as Rb-E2F 
targets throughout the manuscript).  This sample-level enrichment analysis showed that Rb-E2F 
target genes were differentially enriched among the tumors in this data set. A set of tumors was 
significantly enriched for over-expression of Rb-E2F targets (i.e. higher expression values 
compared to other samples) and while another set of tumors show the opposite pattern (Figure 2). 
Some of the tumors with significant up-regulation of this gene set displayed concomitant over-
expression of CDKN2A and MKI67 together with Rb targets CCNE1 and E2F3, which was 
previously shown to indicate compromised Rb signaling[15], although some exhibited no such 
patterns in mRNA levels. Moreover EA with additional gene sets (genes that are differentially 
regulated in fibroblasts undergoing replicative senescence[16] and in fibroblasts that bypass 
RAS-induced senescence[12]) showed that indeed these primary breast cancers were 
differentially enriched for transcriptional programs indicative of evasion of senescence-induced 
stress (Figure 2). Interestingly, these tumors coincided with more aggressive subtypes of breast 
cancer (luminal B and basal-like)[17] and with p53 mutation-carriers. Finally, we assessed the 
prognostic power of Rb-E2F targets finding that it has higher prognostic power than over-
expression of CDKN2A and MKI67[15], which was found to be representative of impaired Rb 
signaling and hence predictive of subsequent tumor events in ductal carcinoma in situ of 
breast[15]. As seen in Figure 2b, while Rb-E2F signature is more informative that the two-gene 
signature (CDKN2A and MKI67) [15], it is similar to another prognostic gene set, chromosomal 
instability (CIN) genes [19]. We also performed survival analysis with Rb-E2F genes in 
pancreas, brain and bladder cancers. In all of them, Rb-E2F target gene signature had prognostic 
power (Supplementary Figure 1a). Thus these results confirmed that sample-level enrichment 
analysis might be used to identify gene signatures that can stratify tumor samples according to 
their outcome.  
 
As many samples with abrogated Rb signaling have p53 mutations we sought to determine if the 
prognostic power of Rb-E2F targets is independent from p53 mutation status. We performed 
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survival analysis in the same data set excluding the samples with p53 mutations. Enrichment 
with Rb-E2F targets is still a strong indicator of relapse even among samples with wild type p53 
(Figure 2c). The same results were obtained in another breast cancer data set (Supplementary 
Figure 2). This indicates that indeed the predictive power of this signature is independent from 
p53 mutation.  
From now on samples with significant enrichment over-expression of Rb-E2F targets are 
referred to as “worse prognosis tumors”, while the ones with opposite pattern are referred to as 
“good prognosis tumors”. 
 
Dependence on DNA Damage Response 
We set out to identify the differentially enriched gene signatures (and hence processes they are 
related to) between the worse prognosis and good prognosis breast tumors. It is known that 
oncogene signaling elicits substantial DNA damage [18], therefore we performed sample-level 
EA with a chromosomal instability (CIN) signature [19] to see if there were any signs of CIN in 
the worse prognosis tumors. Although there are only 25 genes common between the Rb-E2F 
targets (147 genes) and the CIN signature (70 genes) (Table 3), the enrichment patterns for the 
two gene sets show perfect correlation (for the data set GSE4922, Pearson’s correlation 
coefficient is 0.98 with p value < 2.2e-16) indicating that the up-regulation of Rb-E2F gene is 
closely related to transcriptional signs of chromosomal instability. Actually the two gene 
signatures and the genes in their intersection (CIN-Rb-E2F) have very similar prognostic power 
(Supplementary Figure 3).  
Since tumor cells with DNA damage become heavily dependent on DNA repair pathways in 
order to ameliorate the negative effects of excessive damage to DNA[2], this prompted us to test 
if there were any differences between the worse and good prognosis tumors in terms of DNA 
damage signaling. Therefore we performed enrichment analysis with gene modules from Gene 
Ontology biological process categories and from MSigDb. There is a clear positive enrichment 
of genes related to mitotic checkpoint, anaphase-promoting complex, DNA damage response 
(DDR), DNA repair and networks of genes built computationally around key repair proteins 
(modules from Pujana et al.[20]) in worse prognosis tumors (Figure 3a). As shown in Figure 3b, 
compared to other tumor samples, these samples have higher expression levels of DNA 
repair/DNA damage response genes including PARP1/2 and BRCA1/2. It might seem 
counterintuitive to say a tumor suppressor gene, BRCA1, is expressed at high levels in 
aggressive breast tumors, however the DNA repair afforded by these genes might serve to save 
the cancer cell from death due to excessive DNA damage. This observation might be explained 
by non-oncogene addiction (NOA)[2]. NOA is defined as the dependence of cancer cells on 
stress support pathways that are not themselves tumorigenic. NOA hypothesis posits that in 
addition to the classical hallmarks of cancer that confer tumorigenic properties to the cell, cancer 
cells have to hijack pathways that are crucial to tolerate the oncogenesis-associated stress 
environment caused by intrinsic and extrinsic factors. The classical example to this phenomenon 
is the anti-tumor activity of PARP inhibitors in breast cancer patients with BRCA1/2 mutations 
[21]. This observation also points to ideas for specialized therapy strategies for these aggressive 
tumors, which are mainly basal-like and luminal B, based on the possible addiction of these 
tumors on DNA repair pathways. Indeed, very recently, it was shown that combination therapy of 
iniparib (a PARP inhibitor) and chemotherapy, without significant increased toxic effects, 
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improved the clinical benefit and survival of patients with metastatic triple-negative breast 
cancer, a majority of which are also basal-like[22].  
 
 
Dependence on PI3K/Akt signaling 
In addition to genes related to DNA damage response, the samples with impaired Rb signaling 
were also positively enriched for metabolism-related categories such as “protein folding”, 
“translation initiation”, “RNA splicing”, “ribosome biogenesis”, etc. This observation prompted 
us to focus on a specific pathway that plays a crucial role for the regulation of cellular 
metabolism and its coupling to proliferation. Therefore, we collected gene sets related to 
PI3K/Akt pathway and its downstream target mTOR signaling: “genes up and down-regulated in 
Rb-deficient cells treated with rapamycin[23]”, “genes up-regulated in PI3K-hyper-activated, 
hormone resistant cells[24]” and “PTEN mutation signature[25]”. Figure 4 shows that the 
transcriptional program of tumors with impaired Rb signaling are enriched for hyper-activated 
PI3K signaling as well as for genes up-regulated in PTEN mutant cells. Moreover, the 
transcriptional changes induced by inhibition of mTOR by rapamycin treatment in Rb-deficient 
cell lines are exactly the opposite of the gene expression program indicative of abrogated Rb 
signaling. It is known that in the tumor microenvironment, a range of different stress signals 
impinge on cancer cells: mitotic, metabolic, proteotoxic, oxidative, etc[2]. Even if a cancer cell 
can resist programmed cell death or senescence it will still not survive unless it resists hypoxic 
stress signals[1]. Thus dependence of these tumors on mTOR signaling can be explained in the 
light of this idea. Indeed, it was recently shown that loss of TSC2, a negative regulator of mTOR 
is synthetic lethal with Rb deficiency[26]. 
mTOR signaling activates the expression of genes encoding nearly every step of glycolysis and 
the pentose phosphate pathway, as well as critical enzymes in the de novo synthesis of sterols, 
isoprenoids, and fatty acids[27]. We used modules of genes regulated by mTORC1, a molecular 
complex that contains mTOR[27] to check if indeed the tumors with deficient Rb signaling also 
have activation of processes down-stream of mTOR. As expected, the genes up-regulated by 
mTORC1 are also up-regulated in these samples (Figure 4). mTORC1 promotes the expression 
of HIF1A[27]. In agreement with this, wrose prognosis tumors over-express HIF1A along with 
its target VEGF (Figure 4). As mTORC1 has been shown to induce the transcription of genes 
involved in important metabolic pathways[27], we checked the mRNA levels of enzymes from 
glycolysis and pentose phosphate pathway. Indeed, most of these enzymes are up-regulated in 
worse prognosis tumor samples (Figure 5). Together these observations indicate that the tumors 
that show signs of abrogated Rb pathway have activated signaling through mTOR. These results 
suggest two things: First, these tumors might be addicted to pathways related to metabolic stress 
in addition to DNA damage stress. If this is indeed the case, then, secondly, inhibitors of mTOR 
such as rapamycin might be useful for the treatment of these cancers. The observations in this 
and the previous section show that sample-level EA can help pinpoint pathway dependencies in 
different subgroups of tumors, which can be used to design rational therapeutic approaches 
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Rb pathway-deficient tumors indicate worse prognosis in multiple cancer types 
 
Until now, we have identified transcriptional properties of worse prognosis tumors in breast 
cancer. We performed the same enrichment analyses in brain, pancreas and bladder cancer data 
sets. As seen in Figure 5, in all the data sets, there are two groups of tumors: good prognosis and 
bad prognosis. Similar to the observations we had in breast cancer data sets, bad prognosis 
tumors have positive enrichment for Rb-E2F targets and a transcriptional program indicating 
senescence bypass. Moreover, they up-regulate chromosomal instability-related genes, DNA 
damage response genes and exhibit elevated levels of genes related to glycolysis, pentose 
phosphate pathway and fatty acid synthesis. Good prognosis tumors, on the other hand, have 
exactly the opposite transcriptional pattern. These characteristics of bad prognosis shared across 
multiple cancer types are summarized in Figure 6. Each of these properties reflect a mechanistic 





EA is an effective way to analyze the statistically significant gene sets obtained using high-
throughput functional genomics data. In this work, we propose an alternative approach to EA 
analysis of tumor genomics data to detect clinically relevant patient subgroups. Instead of finding 
genes differentially expressed between two groups, we identify differentially enriched modules 
by performing sample-level EA. Moreover, by comparing enrichment results with available 
clinical information, this method enables the understanding of pathways/processes that underlie 
these clinical phenotypes such as survival. We applied our methodology to the study of clinical 
relevance of stress phenotypes in multiple cancer types. Cancer cells must activate appropriate 
responses to a diverse set of stress insults such as oxidative, metabolic, mitotic, DNA damage 
and replication stress, etc. We explored the prognostic power of a signature of genes that are up-
regulated when Rb pathway is impaired in breast, pancreas, brain and bladder. The tumors with 
positive enrichment for this gene signature displayed a transcriptional program pointing to 
evasion of the senescence barrier. In addition, these tumors were strongly related to worse 
prognosis. Moreover, we showed that the prognostic power of the gene set is independent from 
p53 mutation status. Sample-level EA of the worse and good prognosis tumors helped dissect the 
differences between them: Worse prognosis tumors highly expressed genes related to DNA 
damage response and signaling. We observed over-expression of many key DNA damage repair 
genes such as PARP1/2 giving hints about effective therapeutic strategies for these aggressive 
tumors. In addition, worse prognosis tumors also significantly up-regulated mTOR signaling. 
This results point to an over-all shift in metabolism towards glycolysis and pentose phosphate 
pathway in these tumors. Furthermore, it indicates that inhibition of mTOR might be an effective 
therapeutic approach.  
Overall, our methodology helps identify patient subgroups in high-throughput cancer genomics 
data sets based on differential enrichment of tumor samples for functional gene modules. It 
enables detection of gene modules correlating with clinical characteristics such survival and as 
well as the identification of biological pathways/processes that underlie the pathology of 
different patient subgroups. 
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Table and Figure Captions 
Table 1. Tumour profiling data sets used in the study. Each data set contains a number of patients 
with survival information. Source column gives the GEO accession id of the experiment. 
Table 2. Modules of genes used for enrichment analysis. 
Table 3. List of 25 genes in the intersection between Rb-E2F targets and CIN signature 
 
Figure 1. The general schema of the approach. 1) Gene modules relevant to address the 
hypothesis proposed are collected. These gene modules can be obtained from a number of 
sources such as Gene Ontology, KEGG and MSigDB. However, any gene module can be used 
such as genes differentially expressed in some condition or genes found to be bound by a certain 
transcription factor depending on the hypothesis to be tested. 2) High-throughput expression 
profiling of tumor samples with clinical information. In the heat map, purple color indicates 
down-regulation while yellow means up-regulation. 3) Sample-level enrichment analysis of the 
dataset with the modules results in the identification of samples with different enrichment 
patterns. In the enrichment heat map, red indicates significant upregulation of the module while 
blue indicates significant down-regulation. Grey is for not significant results. 4a) Differentially 
enriched modules are studied for their correlation to some clinical feature, in this case, survival. 
Shown here are Kaplan-Meier curves of samples with two different enrichment patterns. 4b) 
Differences between groups in the cohort are described in terms of phenotypes/pathways based 
on EA results. 
 
Figure 2. Rb-E2F target gene set reflects the response status to oncogene-induced stress and 
has prognostic power in breast cancer. a) Heat map of tumor samples as columns and genes or 
modules as rows. Enrichment with gene modules is shown with colors from blue (down-
regulation) to red (up-regulation) while grey values indicate no significant deviation form 
expected median value. Expression levels of genes are shown in colors from purple (low 
expression) to yellow (high expression). The samples with up-regulation of Rb-E2F targets 
include those that up-regulate CDKN2A with concomitant down-regulation of RB1. 
Deregulation of Rb signaling in these samples is reflected in their over-expression of Rb-E2F 
target genes, CCNE1 and E2F3. These samples show a transcriptional program opposite to what 
is observed in senescent cells indicating that they activated transcriptional programs indicative of 
senescence bypass. Shown is a breast cancer data set by Ivshina et al. 2006 (289 samples). b) 
Kaplan-Meier curves for breast cancer patients. The red curve is for the samples with high 
expression of CKDN2A and MKI67 (left panel), positive enrichment of Rb-E2F targets (middle 
panel) and positive enrichment of CIN gene (right panel). The black curves are for the rest of the 
samples. It was shown that the concomitant expression of CDKN2A and MKI67 is related to 
impairment of Rb pathway hence to subsequent tumor event in DCIS of breast. Rb-E2F gene 
signature has a much stronger prognostic power than the two-gene signature and is very similar 
to the CIN signature. c) Kaplan-Meier curves for patients with breast cancer and without p53 
mutations. The red curve is for the samples with positive enrichment of particular gene sets as 
indicated. Survival analysis shows that the predictive power of Rb-E2F target genes is 
independent from p53 status. 
 
“main-gunes” — 2011/6/7 — 13:52 — page 107 — #119
  9 
 
Figure 3. Tumors with upregulation of Rb-E2F gene set are addicted to DNA repair. Heat 
map of tumor samples as columns and genes or modules as rows. Color codes are as described in 
Figure 2. The top part of the heat map shows the status of p53 in each sample. The samples with 
up-regulation of Rb-E2F signature significantly up-regulate genes annotated with DNA 
damage/repair-related categories and gene signatures related to DNA damage signaling network 
around ATM-BRCA1 (from MSigDB). Shown in the lower part are selected genes involved in 
DNA damage repair.  
 
Figure 4. Dependence on PI3K/Akt signaling. Heat map of tumor samples as columns and 
genes or modules as rows. Color codes are as described in Figure 2. The samples with positive 
enrichment for Rb-E2F signature significantly up-regulate gene signatures of activated PI3K-
mTOR signaling. mTOR is an important modulator of metabolism and can be inhibited by 
rapamycin. The targets of mTOR are also up-regulated in the same tumors. Hence, this 
dependence on mTOR could be exploited therapeutically.  
 
 
Figure 5. Worse prognosis tumors have similar properties in different cancer types. The 
panels are for brain, pancreas and bladder from top to bottom. For each cance type, four 
properties are shown. The color codes for expression (yellow-to-purple) and enrichment analysis 
results (red-to-blue) are the same as in Figure 2. The properties are up-regulation of 1) Rb-E2F 
genes and a transcriptional program of senescence bypass 2) chromosomal instability-related 
genes 3) DNA damage response gene and 4) metabolic pathways regulated of HIF1a.   
 
Figure 6. Transcriptional properties of worse prognosis tumors. 1) In normal cells, oncogene 
signaling induces the CDKN2A locus. The two protein products of this locus, Arf and INK4a, 
activate p53 and Rb proteins, respectively, which results in the induction of senescence. When 
Rb is functional, it prevents transcription from E2F target genes. In worse prognosis tumors Rb 
signaling is impaired, hence, Rb-E2F targets are up-regulated. At the same time, genes normally 
downregulated in senescence cells are upregulated while genes down-regulated in senescence are 
up-regulated in worse prognosis tumors. 2) Worse prognosis tumor up-regulate a gene signature 
that indicates chromosomal instability (CIN). 3) Oncogene activation induces DNA damage, 
which leads to a DNA damage response. Various repair pathways are activated. Worse prognosis 
tumors significantly up-regulate DNA damage response genes. 4) Tumor cells alter metabolic 
pathways in response to metabolic stress induced by oncogenic signaling. Worse prognosis 
tumors depend on mTORC1/HIF1a signaling. The result is up-regulation of glycolysis, pentose 
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Supplementary Figure 1. Predictive power of Rb-E2F gene signature in pancreas, bladder 
and brain cancer data sets. Kaplan-Meier curves for patient cohorts of bladder, pancreas and 
brain cancer are shown. The red curve is for the samples with positive enrichment of Rb-E2F or 
CIN-Rb-E2F genes signature. These samples have worse survival compared to all the other 
samples in each data set (black curve). 
 
Supplementary Figure 2. The predictive power of Rb-E2F signature is independent from 
p53 mutation status. Kaplan-Meier curves for a patient cohort of breast cancer. The red curve is 
for the samples with positive enrichment of Rb-E2F genes signature. These samples have worse 
survival compared to all the other samples in each data set (black curve). 
 
Supplementary Figure 3. Comparison of the predictive powers of the CIN signature and 
Rb-E2F target genes. Kaplan-Meier curves for patients with breast cancer. The red curve is for 
the samples with positive enrichment of particular gene sets as indicated. The black curve is for 
the rest of the sample. Genes in the intersection of the two signatures (CIN-Rb-E2F) perform 
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Rb-E2F interaction network 
built computationally using 
protein interaction databases 147




A signature upreg in 
chromosomal instability and 
predictive of clinical outcome 70




Genes downreg in fibroblasts 
that bypass RAS-induced 
senescence 3030
Braig M et al., Nature, 
2005
Up in senescence 
bypass
Genes upreg in fibroblasts that 
bypass RAS-induced 
senescence 2714
Braig M et al., Nature, 
2005
Down in replicative 
senescence
Genes downreg in fibroblasts in 
replicative senescence 6122
Pazolli E et al., 
Cancer Res, 2009
Up in replicative 
senescence
Genes upreg in fibroblasts in 
replicative senescence 6048




Computational network around 
Atm built using expression 
profiling and functional and 
1041 Pujana MA et al., 
Nature Genetics, 2007




Computational network around 
Brca1 built using expression 
profiling and functional and 
genomic data 1198




Computational network around 
Brca2 built using expression 
profiling and functional and 
genomic data 305




Computational network around 
Chek2 built using expression 
profiling and functional and 
genomic data 559




Computational network around 
Xprss built using expression 
profiling and functional and 
genomic data 118
Pujana MA et al., 
Nature Genetics, 2007
Up in Rb-deficient 
cell line treated 
with rapamycin
Genes up-regulated in Rb-
deficient breast cancer cell line 
treated with rapamycin 333
Akcakanat A et al., 
Mol Cancer, 2009
Down in Rb-
deficient cell line 
treated with 
rapamycin
Genes down-regulated in Rb-
deficient breast cancer cell line 
treated with rapamycin 100






Gene up-regulated in hormone 
therapy resistant breast cancer 1475




PTEN mutation signature upreg 
in PTEN-mutant breast cancer 592
Saal LH et al., PNAS, 
2007
Up in TSC1 
mTORC1
genes upreg in Tsc1-/- mutant 
vs. WT MEFs 167
Duvel K et al., Mol 
Cell, 2010
Down in TSC1 
mTORC1
genes downreg in Tsc1-/- 
mutant vs. WT MEFs 101
Duvel K et al., Mol 
Cell, 2010
Table 3
Ensembl id Gene symbol Description
ENSG00000071539 TRIP13 thyroid hormone receptor interactor 13
ENSG00000073111 MCM2 minichromosome maintenance complex component 2
ENSG00000087586 AURKA aurora kinase A
ENSG00000093009 CDC45 cell division cycle 45 homolog (S. cerevisiae)
ENSG00000094804 CDC6 cell division cycle 6 homolog (S. cerevisiae)
ENSG00000106462 EZH2 enhancer of zeste homolog 2 (Drosophila)
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ENSG00000111247 RAD51AP1 RAD51 associated protein 1
ENSG00000111665 CDCA3 cell division cycle associated 3
ENSG00000112742 TTK TTK protein kinase
ENSG00000112984 KIF20A kinesin family member 20A
ENSG00000114346 ECT2 epithelial cell transforming sequence 2 oncogene
ENSG00000117399 CDC20 cell division cycle 20 homolog (S. cerevisiae)
ENSG00000117650 NEK2 NIMA (never in mitosis gene a)-related kinase 2
ENSG00000121152 NCAPH non-SMC condensin I complex, subunit H
ENSG00000123975 CKS2 CDC28 protein kinase regulatory subunit 2
ENSG00000131747 TOP2A topoisomerase (DNA) II alpha 170kDa
ENSG00000132646 PCNA PCNA antisense RNA (non-protein coding)
ENSG00000134057 CCNB1 cyclin B1
ENSG00000134690 CDCA8 cell division cycle associated 8
ENSG00000157456 CCNB2 cyclin B2
ENSG00000164109 MAD2L1 MAD2 mitotic arrest deficient-like 1 (yeast)
ENSG00000164754 RAD21 RAD21 homolog (S. pombe)
ENSG00000168496 FEN1 flap structure-specific endonuclease 1
ENSG00000171848 RRM2 ribonucleotide reductase M2
ENSG00000198901 PRC1 protein regulator of cytokinesis 1
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upregulation of metabolic pathways 
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5.1 IntOGen et al.
Cancer is a complex disease typically characterized by the occurrence of
different types of alterations. Hence, as stated before, it is crucial to take
into consideration data related to these different oncogenic factors. As
discussed in the objectives section, the first and primary purpose of this
thesis was to create a cancer genomics resource that integrates informa-
tion from oncogenomic studies analyzing distinct types of alterations. To
this end, as explained in Chapter 2, we generated IntOGen, a web tool
for the study of cancer. However, more than another web-based tool, In-
tOGen is ’the concept of integration’. Even if oncogenomic data may be
updated and the analysis methods changed, the basic idea, which is ’to
bring together different sources of information’, will be the same. Hence
IntOGen is a project that will evolve continuously incorporating new fea-
tures and data. There are many ways it could be extended. Nevertheless,
we designed the system so that it would be easy to incorporate new com-
ponents. In the following sections, I describe some of the ways the system
can be improved.
5.1.1 Integrated Alteration Scores
The current version of IntOGen analyzes each alteration type separately
and does not attempt to merge the analysis results for different alteration
types. It would be interesting to calculate an integrated alteration score.
Efforts in this direction are already in progress. In our group, recently,
such an integrative approach was applied to detect mutations with conse-
quences. This method, Condel, integrates the results from different tools
to calculate a score that is a measure of the consensus between all the
tools. The higher the consensus, the higher the probability of the muta-
tion having functional consequences. A similar approach can be used to
perform a true integration of the oncogenomic data for expression, copy
number aberration and mutations etc.
126
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5.1.2 Addition of New Types of Alterations
Currently IntOGen contains mRNA expression profiling, copy number
analysis data sets and mutational data. This is mainly because these meth-
ods have been in use for a longer time, the methods to analyze them are
more established and there is more data available. However, other types
of alterations have to be included to get a complete view of the oncoge-
nomic landscape. The current pipeline requires at least 20 tumor samples
and one normal sample in a data set. Therefore the new data has to be big
to be included. Fortunately, as high-throughput data related to other alter-
ations become available it can easily be incorporated to the system. Some
of these types of data include miRNA and other non-coding RNA expres-
sion profiling, DNA methylation and histone profiling. In the pipeline,
appropriate methods specific to each data type have to be implemented
and in the web service, each new type of alteration can be presented as
an additional column. Although most are not big enough, GEO already
has some studies that include these alterations. However, maybe the best
source of data for IntOGen is cancer genome projects. These projects
include a large number of tumor samples for many different types of al-
terations. For example, TCGA analyzes microarray for expression profil-
ing for both mRNA and miRNA, SNParrays for copy number profiling,
methylation arrays for DNA methylation profiling and sequencing for a
set of genes in the same tumor sample. Hence this valuable data has to
be included as soon as they become available. Another cancer genome
project, ICGC, on the other hand, performs NGS-based surveys of tran-
scriptomes, genomes etc. However due to the nature of this data, there are
many more requirements in order for it to be included. This is discussed
in the next section.
5.1.3 NGS Data in IntOGen
Currently IntOGen includes platform-based data. Each platform is dif-
ferent. For example, even if they are both single channel platforms, Il-
lumina BeadArray data cannot be mixed with Affymetrix data. So the
studies using them cannot be pooled together. To overcome this prob-
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lem, we decided to analyze each study separately, map the results to En-
sembl genes and combine the gene-level data to obtain a single value.
Because of this, currently IntOGen is gene-centric. Hence differences be-
tween cancers are described in terms of protein-coding genes. However,
due to rapid advancements in sequencing technologies, there is a shift to-
wards NGS-based techniques. In the future, this type of data is expected
to grow thanks to cancer genome projects such as ICGC. Soon enough
deep sequencing data for the genomes, transcriptomes, methylomes, etc
will be available for a large number of patients. In this type of data, the
results are mapped to a position in the genome, greatly unifying the re-
sult even if different sequencing methods are used. However this type of
data requires different analysis methods than platform-based data. New
pipelines has to be implemented to detect significantly altered genes in a
study using such type of data. Even the functional enrichment analysis
for deep sequencing-based data should be different. Fortunately, in our
group, pipelines for this analysis are already being built in anticipation of
future requirements. Another sine qua non for NGS data is the adapta-
tion of the web service. Although it is not published yet, we have already
developed a genome browser view as part of an extension of IntOGen to
publish ICGC data.
5.1.4 Translational IntOGen
While designing IntOGen, we were interested in detecting the alterations
taking place in cancer with respect to normal samples. However, there are
other biologically important questions that could be addressed with the
type of data we have in IntOGen. Some of these questions are described
in the following paragraphs. To be able to do the kind of analysis to
answer these questions, we first need oncogenomic data sets with detailed
clinical information and an annotation system to encode this information
in a automatically accessible way. We have already created an ontology
for this purpose and the sample annotations are being converted to this
new system. In addition to data, statistical pipelines for analysis and an
appropriate web application should be implemented. Both of these can be
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prepared using the software already created in the group.
a. Which patients will have aggressive disease after a local can-
cerous lesion is removed? This is a clinically very important is-
sue especially for epithelial cancers. For example, in the case of
breast cancers, not all the patients with ductal carcinoma in situ will
progress to a malignant stage and will need chemotherapy treatment
after the removal of the tumor. Hence, there is a high probability of
over-treatment if all patients are treated the same. If we knew who
would not need further treatment, we would save the patient of the
physical and economic burden. To be able to perform analysis to
answer this question, we need big cohort of patients with detailed
clinical information similar to the ones used in chapter 4. We have
already collected and annotated a large amounts of such data sets.
Another requirement is statistical methods such as cox proportional
hazards model. Actually many such useful methods are available in
the R Bioconductor project. Therefore, incorporation of R into In-
tOGen pipeline would be greatly useful to create pipelines for this
kind of analysis.
b. Which patients will respond to a certain treatment? This knowl-
edge is crucial for the personalized treatment of the patients. There
is always a risk of recurrence after non-specific treatment meth-
ods such as chemotherapy. However, the real contribution would
be in targeted therapies. The cost of treatment would be greatly
reduced since this type of therapy is very expensive. For exam-
ple, trastuzumab, a monoclonal antibody that interferes with the
HER2 receptor, is implicated for the treatment of HER2-positive,
node-positive breast cancer patients. The average wholesale price
of trastuzumab is $2,928.89 for 440 mg. For a 70-kg woman, each
2-mg/kg dose would cost about $1,000, and a yearly regimen would
cost about $50,000. This is a great economic burden for both the
patient and the social security system. So it would be an advantage
to be able to predict who might benefit from the treatment. For this
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kind of analysis, data and analysis requirements are similar to the
one in the previous section.
c. Which subtype of cancer does the patient belong to? Cancer is
a heterogeneous disease. There are usually subtypes that are char-
acterized by the alterations in a specific pathway and have a dif-
ference in survival. For example, in the case of breast, basal-like
and luminal B subtypes are more aggressive and have worse sur-
vival than the others. So stratification of patients into such subtypes
has clinical importance. For this analysis, an approach similar to
the analysis we did in chapter 4 can be used. This is described in
the corresponding section. Another widely used method to detect
different groups in high-throughput data is clustering. Once patient
subgroups are identified various data mining methods can be used
to extract gene signatures that can be used to classify other data
sets. Once again, all these statistical methods can be incorporated
to the system using R Bioconductor.
5.1.5 The Biomart Interface
All the results of the pipeline are available in the web service. How-
ever, there was a need for a system to enable bulk download of data. We
generated a Biomart interface for IntOGen for this purpose. This work
is covered in Chapter 3. Biomart is a query-oriented data management
system for biological data. Biomart provides similar viewing and query
options unifying the retrieval and visualization of biological data. The
data is organized as databases that have tables. The rows in the tables
can be filtered using the filter options. The attribute options can be used
to determine which information is to be retrieved for each row. Using
this interface, large amounts of data can be retrieved with simple queries.
Now IntOGen users can download all or parts of IntOGen data with sim-
ple queries.
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5.2 Sample-level Enrichment Analysis
Differentiating patients with different characteristics is of great impor-
tance in the clinical management of cancer. The typical approach is de-
tecting genes differentially expressed between different patients groups.
These genes are later on analyzed with a functional enrichment method
to determine if there is any biological property that could explain their
deregulation. For the work described in the previous chapter of my thesis,
I wanted to test the usefulness of a different approach to detect patient
subgroups. According to this approach, instead of detecting differentially
expressed genes, I used a methodology to identify differentially enriched
gene modules. This method is based on sample-level enrichment analysis
of all the samples in a data set. It could be used to stratify patients with re-
spect to clinically important characteristics such as survival or mutational
status for a gene. Moreover, hypotheses can be tested using relevant gene
modules. For example, based on the importance of senescence as a tumor
suppressive mechanism, I wanted to determine if a gene signature related
to the deregulation of senescence-relaying Rb pathway could have prog-
nostic power in multiple cancers. I saw that all the data sets were divided
into two groups of samples: samples with significant up-regulation of the
Rb-E2F target gene signature and those with the opposite pattern. Sur-
vival analysis showed that the first group has significantly worse survival
than the second group. Moreover the dissection of the transcriptional pro-
files of worse prognosis tumors showed that they depend on various stress
pathways. These results show that sample-level EA can be used to detect
patient subgroups and provide a birds-eye view of the differences between
them. This result can be reasoned as follows: Different genes from the
same pathway might be altered in the same tumor having the same net ef-
fect on the pathway. Hence although the samples might be different at the
level of genes, their are not so at a more general level, at the level of path-
ways. Sample-level EA can help extract such patterns giving hints about
the biological reasons why the two patient groups could be different. For
example, the deregulation of Rb-E2F signaling might be achieved by dif-
ferent ways: Rb mutations, copy number gain in E2F genes, etc. However
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the net effect is the activation of Rb-E2F target genes. Sample-level EA
might help such similarities or dissimilarities between different patients.
This methodology can be used in the translational version of IntOGen
described in the previous section. Instead of detecting genes that are dif-
ferentially expressed between the samples in a data set using OncoZ (see
the IntOGen paper in chapter 2), a large number of gene modules can be
used to identify module-level differences between different tumors. This
is based on the idea that different subtypes depends on the alteration of
different pathways. For example, our analysis showed that basal-like car-
rier breast cancers might highly depend on DNA damage repair pathways
and hence be sensitive to inhibition of PARP genes while ER+/PR+ breast
cancer are not expected to be so. In addition to pathway-level differenti-
ation of individual tumors, tumor samples can also be stratified with re-
spect to their chance of response to a drug, if modules related to response
to a specific drug are used, for example. In a similar way, hypthesis-driven
sample-level analysis can help test other clinically important properties
similar to the way we showed that stress phenotypes are important for
worse prognosis tumor as described in chapter 4.
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The main points of the work presented in this thesis can be summa-
rized as follows:
1. The analysis of tumorigenesis requires an integrative approach. For
this purpose, we provide IntOGen, a web-based oncogenomics re-
source.
2. IntOGen brings together transcriptional, copy number and muta-
tional profiling data sets for many different tumor types.
3. We provide results at different levels of complexity: genes to mod-
ules and studies to combinations of studies.
4. IntOGen continues to evolve incorporating new components, data
sets and analysis methods.
5. Sample-level enrichment analysis can be used to stratify patients
into clinically meaningful groups.
6. Positive enrichment for Rb-E2F target genes is an indicator of a
senescence-evasive transcriptional program and worse prognosis in
multiple cancer types.
7. Worse prognosis tumors show transcriptional signs of chromosomal
instability and dependence on certain stress pathways such as DNA
damage repair and metabolic stress through mTOR signaling.
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